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Abstract 
 
Quorum sensing is a type of bacterial cell-cell communication that uses diffusible signaling 
molecules to allow the regulation of gene expression based on cell density. The two types of 
signaling molecules discussed here are autoinducer-2 (AI-2) and a class of signaling molecules 
of the N-acylhomoserine lactone type (AHL) also known as autoinducer-1 (AI-1). The 
biosynthesis of both of these molecules has origins in a metabolic pathway. Although 
undisputed in some cases, the role of AI-2 and AHLs in bacterial systems has come into 
question. Here, the functionalities of these molecules were investigated by utilizing isotope-
labeled versions of both AI-2 and AHLs in conjunction with liquid chromatography tandem mass 
spectrometry in order to quantify the natural abundance of these molecules in various bacterial 
cultures. Presented in this thesis are, a synthesis for doubly-deuterated AHLs as well as 
chromatographic and spectrometric methods for the detection and quantitation of these 
molecules. Additionally, a series of relevant biological studies which effectively and prolifically 
utilize these synthetic and analytical techniques are presented here.  
The selective destruction of beta-cell mass in the Langerhans of the pancreas is known to 
cause Type 1 diabetes mellitus (T1DM). Currently, many key aspects of this autoimmune 
disease remain unclear, including the exact mechanism of beta-cell death. In a collaborative 
project with Dr. J. Jason Collier, we sought to test the hypothesis that different mechanisms of 
cell death will present discrete phenotypic profiles which can be distinguished by a specific 
metabolic response in response to the appropriate stimuli.  A second project presented in this 
thesis is the development and implementation of a method to profile the metabolic signatures of 
two types of pancreatic beta-cell death using tandem mass spectrometry techniques. Using 
832/13 rat insulinoma cells, the metabolite pools of cells exposed to either pro-inflammatory 
cytokines or known apoptosis inducers, such as camptothecin, were analyzed. In this 
investigation, it was found that this method was effective in defining reproducible metabolic 
differences in each sample tested. Taken together with complementary methods used in the 
Collier lab, the results collectively demonstrate that pancreatic beta-cells undergo apoptosis in 
response to camptothecin, but not pro-inflammatory cytokines. 
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Introduction 
 
Life in all of its forms is fundamentally chemical in nature. At the unique intersection of chemistry 
and biology, chemistry is the universal language which governs all biological systems.  Over the 
years, the discipline of chemical biology has grown to include the tools of the core disciplines of 
chemistry such as analytical and synthetic chemistry. Applications of these tools have been 
essential for the probing and understanding of relevant biological problems and questions 
because many of them are in fact rooted in chemistry. The two systems, whose studies 
provided the subsequent results detailed in this thesis, were investigated principally by 
variations of liquid chromatography-tandem mass spectrometry techniques. 
 
The first system presented is the primary cell-cell communication systems of bacterial species. 
These systems, termed quorum sensing, are a method by which bacteria use small molecules 
to send information about the status of their population density and possibly their immediate 
environment. The variety of platforms used to study these systems are expansive, ranging 
anywhere from genomics to classical analytical techniques. The immediate goal surrounding 
research of these systems also varies. Quorum sensing pathways continue to be newly 
identified in different species of bacteria and in different environments. Alternatively, the 
purpose for studying quorum sensing could be to determine why these systems are present and 
for what purpose they ultimately serve. The studies presented in Chapter I of this thesis will 
focus on the quantitation of the small molecules involved in quorum sensing in different bacterial 
species in an effort to better define the exact nature of quorum sensing systems.   
 
The second system of interest is the global metabolism of rat insulinoma cells. These cells will 
serve as a model for the human pancreatic islet cells affected by the autoimmune disease, Type 
1 Diabetes mellitus (T1DM). Although the destruction of these cells is known to cause T1DM, 
the exact mechanism of death is unknown. Consequently, the delineation of this mechanism is 
essential for the advancement toward a cure. Most of the current studies focus on the genomic 
manipulation of pathways which are known to be involved in T1DM. From a chemical 
standpoint, the studies presented in Chapter II will focus on profiling the metabolism of rat 
insulinoma cells in order to better understand possible mechanisms thought to be responsible 
for pancreatic islet cell death. 
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Chapter 1 
Achieving a Quantitative Understanding of Quorum Sensing  
3 
 
Abstract 
 
The quorum sensing signal Autoinducer-2 (AI-2) is thought to be an interspecies signal, and 
while its signaling abilities are not disputed in all cases, there has been evidence of an 
alternative use for AI-2.  Its biosynthesis is linked to the activated methyl cycle, which has raised 
the question as to whether its function is strictly signaling, metabolic or a combination of the two. 
Conversely, only gram negative bacteria are known to produce the quorum sensing signals N-
acyl homoserine lactones (AHLs) or Autoinducer 1 (AI-1). These molecules are produced by an 
intersection of two biosynthesis pathways that ordinarily serve unrelated metabolic functions. 
Often, one species will produce more than one AHL and/or integrate a different class of quorum 
sensing molecules such as AI-2. Our lab has designed a strategy for the determination of the 
role of AI-2 through detection and quantification, and previous studies employing these 
strategies have led to a basic definition of quorum sensing. Currently, there are no such tools 
available for the quantitation of AI-1s. From here we aimed to develop a similar set of tools for 
the detection and quantitation of AHLs. First, we have designed and carried out a synthesis of 
stable isotope labeled AHLs that incorporates the use of solid phase techniques, and can 
produced any AHL sought-after, due to the strategic placement of the isotope into the 
conserved lactone core. With these stable isotope labeled standards in hand, we then sought to 
develop chromatographic and spectrometric methods in order to use the technique of isotope 
dilution tandem mass spectrometry. Using all the tools developed by our lab, we were able to 
accurately quantitate exact concentrations of AHLs from biological samples, as well as continue 
to probe these species for AI-2 production, to begin to understand the relationship between 
these different quorum sensing systems. 
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Background and Significance 
 
For many years it had been postulated that the bacterial world possessed a means by which 
cooperative behaviors could ensure that the efforts of many outweighed the efforts of few. It was 
noted that the communal nature of bacteria was beneficial for survival.1 While intrinsically 
interesting, the methods by which many bacteria communicate with each other are of particular 
interest because of their physiological implications. One of these methods consists of the 
synthesis, accumulation, and recognition of small diffusible molecules that has been termed 
quorum sensing.2-4 Quorum sensing was first discovered decades ago, but it has gained interest 
recently due to the role this mechanism plays in biofilm formation.5-7 Understanding the 
underlying mechanisms of biofilm formation is of importance because of the role they play in 
chronic infections persistent in diseases such as cystic fibrosis.8-10 Several pathogenic bacteria 
have been found that produce quorum sensing-dependent biofilms, and many of them are 
antibiotic resistant. The ability to interrupt these quorum sensing pathways could potentially lead 
to novel anti-infective agents that have several advantages over traditional agents.11, 12 
 
Though many significant discoveries have been made, there is still more to be understood about 
quorum sensing and the molecules involved. One basic problem is the lack of a definition of the 
term quorum sensing. Currently, the term is used to encompass all phenotypic expressions 
which are found to be regulated by the production and recognition of diffusible chemical signals, 
regardless of whether the purpose is to transmit information on local cell density. However, it is 
becoming more evident with increasing interest, that the pathways and mechanisms of quorum 
sensing circuits are more dynamic, diverse and complex than originally thought.13-15 For 
example, there are now many reports of bacteria that posses quorum sensing machinery, yet do 
not employ quorum sensing molecules in order to measure cell density. Conversely, other 
bacteria utilize multiple quorum sensing molecules and systems in order to regulate a single 
behavior. There are many questions about this sometimes oversimplified mechanism that need 
to be answered if a definite and comprehensive understanding of quorum sensing molecules 
and pathways is to be achieved.  
 
The analytical techniques that have been used previously have been focused toward the 
detection of these quorum sensing molecules in biological systems. If the original thought that 
the production of these molecules is strictly a means for bacteria to essentially “count” cell 
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numbers, then quantifying these molecules should be the next logical step in determining the 
information content of signaling molecules. It is our belief that characterizing the function of 
quorum sensing on an individual basis will begin with the quantitation of quorum sensing 
molecules. The work presented in this chapter is built upon the tools previously employed by our 
lab for the quantitation of quorum sensing molecules, and demonstrates the effectiveness of 
synthetic isotopically labeled internal standards coupled with unbiased and sensitive analytical 
techniques for quantiation in a variety of bacterial species. 
 
Quorum Sensing 
Quorum Sensing is the term that has been given to the unique capability by which bacterial 
communities monitor population and adjust behaviors accordingly, allowing them to adapt to 
different environmental factors and cues.  This is accomplished by a variety of small diffusible 
signaling molecules, and there are now many known examples of signaling mechanisms in a 
broad range of bacteria that act as quorum sensing systems. The mechanisms have been 
shown to be cell density dependent; while each single cell may emit a low concentration of 
these small molecules, at high cell densities high concentrations of signal will consequently be 
reached4, 6 (Figure 1). Thus, a quorum is necessary for the community to recognize its own 
minimal population density in order to regulate gene expression. The physiological processes 
and behaviors that are regulated by the gene expression resulting from quorum sensing are 
usually thought to be beneficial to the population and can range anywhere from biofilm 
formation to virulence depending on the species.16 Other examples include motility, 
bioluminescence, and anti-biotic resistance.17-19 One of the genes regulated by quorum sensing, 
discovered in early studies, is the production of the signaling molecules themselves which gives 
them their common name autoinducers (AI).  
Figure 1: Quorum sensing is cell density dependent. 
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Quorum sensing can be interspecies or intraspecies. Major classes of intraspecies signaling 
systems include those of gram negative bacteria, which produce N-acyl homoserine lactones 
(AHLs), or autoinducer 1 (AI-1s)1, and gram positive bacteria, which produce cyclic peptides 
(AIPs)20. The interspecies signals that are variations of (S)-4,5-dihydroxy-2,3-pentandione 
(DPD), are known as AI-2, and have been found in both gram positive and gram negative 
bacteria21.  Both types function similarly. The work presented in this thesis will focus on 
intraspecies AI-1 molecules as well as the interspecies AI-2 signaling molecule.  All AIs will be 
profiled in strains that utilize one or both signaling systems. The relationship between the two 
signaling pathways will be examined in species possessing both systems.  
 
AI-2 Mediated Quorum Sensing 
Initially, it was thought that a quorum sensing molecule produced by a particular species was 
the primary means by which that species “talked” among its own kind. However, the only known 
quorum sensing signal common to both gram negative and gram positive bacteria, AI-2, is used 
throughout a wide variety of bacteria. The molecule was first discovered in the bioluminescent 
marine organism Vibrio harveyi22, and its structure was finally elucidated in 2002.23 AI-2 in its 
active form has many different chemical forms. Each species may recognize a different 
chemical from. As shown in Scheme 1, it can spontaneously rearrange and can also hydrate or 
borate. Its synthetic precursor, DPD, is synthesized by the enzyme (S) ribosyl homocysteinase,  
 
 
Scheme 1: (S)-4,5-dihydroxy-2,3-pentandione (DPD) can spontaneously rearrange, hydrate, or borate 
to form multiple chemically active forms. 
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(LuxS).24 LuxS was identified as the AI-2 synthase in 1999, although this enzyme had previously  
been described in 1968 as a part of the activated methyl cycle.25  This enzyme is well 
conserved; nearly half of all sequenced bacteria, both gram positive and gram negative, contain 
a LuxS homologue lending support to the idea that AI-2 is an interspecies signal.21 Throughout 
this text, the terms DPD and AI-2 will be used interchangeably.  
 
N-Acylhomoserine Lactone Mediated Quorum Sensing 
Many gram negative bacteria produce one or more acylated homoserine lactone molecules to 
be utilized as signaling molecules. AHL-mediated quorum sensing was first identified in V. 
fischeri.26 The molecule produced was identified as (3S)-N-[3-oxo-hexyl]-homoserine lactone. 
From here, several other signaling systems were identified in a wide range of species.1 Once 
thought to be unique to marine bacteria, it is now clear that AHL signaling is a well conserved 
regulatory system that is widespread throughout proteobacteria.27, 28 The process by which 
quorum sensing bacteria produce and utilize AHLs has been extensively studied and is 
relatively well characterized. Mechanistically, it is fairly simple. Acyl homoserine lactones are 
synthesized by a family of proteins of the LuxI-type. When the quorum is reached, another 
protein, encoded in the same lux operon, of the LuxR-type detects and interacts with  
 
 
 
Scheme 2: A proposed mechanism for the biosynthesis of N-acylhomoserine lactones (AHL).  
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the AHLs, which then causes changes in genotypic and phenotypic expression by 
transcriptional activation.29 These complexes catalyze the formation of the amide bond between 
the amino group of S-adenosyl methionine (SAM) and the acyl chain from an acyl carrier protein 
(ACP).6 Scheme 2 depicts a proposed mechanism by which AHLs are synthesized by LuxI. The 
acyl chains can vary in length but are usually even numbered due to the fact that they originate  
in lipid synthesis pathways. They may also be unsaturated, have branching or be oxidized in the 
3 position (Figure 2). AHLs are named by the chain length and by additional substitution in the 3 
position. Given that the synthesis of these molecules involves the integration of two biological 
pathways that ordinarily serve different purposes, it raises the question as to whether quorum 
sensing is strictly that, or if there is a metabolic implication for the production of AHLs.  
 
Biosynthesis of Quorum Sensing Molecules 
The activated methyl cycle (AMC) is a major metabolic pathway responsible for the recycling of 
sulfur containing amino acids as well as the methylation of important biomolecules such as DNA 
and RNA.30 In this cycle S-adenosyl methionine (SAM) is produced by a reaction with 
methionine and adenosine triphosphate (ATP), catalyzed by the enzyme MetK. SAM is then 
converted into S-adenosyl homocysteine (SAH), and then detoxified to generate S-ribosyl 
homocysteine (SRH). The pinnacle enzyme LuxS, which catalyzes the conversion of SRH to 
homocysteine, is consequently responsible for the production of AI-2 in the same process. The 
conversion of homocysteine back to methionine then completes the cycle, as shown in Figure 3. 
Figure 2: N-acylhomoserine lactones (AHLs). AHLs are named by their chain length and by 
substituent in the 3 position. 
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AI-1 or AHL production is also linked to the activated methyl cycle, as it is synthesized directly 
from SAM by LuxI. Further, the acyl chain of ALHs is delivered directly from an acyl carrier 
protein either from lipid synthesis pathways. The realization that both of these quorum sensing 
molecules are tied to biological pathways that ordinarily serve an alternative purpose, has raised 
questions as to the purpose of these molecules in various bacterial species. An alternative 
thought is that the production of these molecules is simply a metabolic side product.  
 
Vibrio harveyi and Escherichia coli Background 
The quorum sensing circuit that utilizes AI-2 was first discovered in Vibrio harveyi, and since 
then, several homologues of LuxS have been identified in a wide variety of bacteria.23 V. harveyi 
also utilizes AI-1 quorum sensing. It has been shown that this species uses both of these 
systems to regulate bioluminescence and that their biological pathways converge. Because of 
this unique intersection it has been hypothesized that the integration of these two different 
systems allows V. harveyi to identify itself from other species.31  
Figure 3: The Activated Methyl Cycle. Both AI-2 and AHL production are linked to the activated 
methyl cycle. LuxS catalyzes the formation of homocysteine from SRH while also producing DPD. AI-
1s, or AHLs, are produced from SAM by the enzyme LuxI. 
Homocysteine
Methionine
SAM
SAM
SRH
LuxS
LuxI
Activated 
Methyl 
Cycle
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Escherichia coli is of interest due to the fact that it is known to contain AI-2 producing and 
transporting enzymes, although it does not appear to use them for quorum sensing signaling.21 
Of interest is the AI-2 receptor, LsrB, which upon recognition of AI-2, upregulates the 
importation and catabolism of AI-2.21, 32 This has led to the belief that AI-2 has a strictly 
metabolic purpose in E. coli.  In studies conducted by our lab, these two species were selected 
for investigation in order to gain a molecular definition of quorum sensing.33 The central 
hypothesis was that if the bacterial species of interest was indeed using AI-2 to transmit 
information about cell density, then the concentration of AI-2 per cell number should remain 
constant under all conditions, including time, growth phase and most importantly, nutrient 
conditions.  DPD concentrations in E. coli, and DPD and HAI-1 (AI-1 produced by V. harveyi) 
concentrations in V. harveyi were monitored as cultures grew from exponential to stationary 
phase. Each species was grown with one of four different glucose concentrations, 0.0, 0.08, 
Figure 4: Landscape depictions of AI signal/cell density ratios, and AI synthesis rates. (A) E. coli is 
unable to regulate [DPD]/cell density ratio. (B) V. harveyi is maintains this ratio. (C) [HAI-1]/cell density 
ratio increases slightly for V. harveyi. (D) Over 45 minute intervals, the rate of production of DPD 
decreases, while the rate of production of HAI-1 is constant for V. harveyi. 
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0.14, or 0.20% (w/v). As glucose concentrations increased, i.e. added nutrients increased, 
neither E. coli nor V. harveyi demonstrated a considerable increase in cell density. It was found 
that [DPD]/cell density in E. coli varied from 4.8 ± 0.5 to 39 ± 4.8 µM/OD600, indicating that E. 
coli is not capable of regulating cell density information without regulation of metabolism (Figure 
4A). Conversely, [DPD]/cell density in V. harveyi remained nearly constant under all the glucose 
concentrations (Figure 4B), indicating its use as a quorum sensing signal. When [HAI-1]/cell 
density was examined, the ratio did increase from 0.7 ± 0.2 to 6.6 ± 0.4 µM/OD600. (Figure 4C), 
however with added glucose concentrations, [HAI-1] showed no significant changes during 
exponential phase. This led us to believe that HA1-1 is not used as a quorum sensing signal in 
V. harveyi. Additionally, the rate at which V. harveyi produces DPD decreased over time, while 
the rate of production of HAI-1 stayed constant (Figure 4D). The initial studies of these two 
species are what led to the following definition of quorum sensing33: 
 
                                  
            
           
 
These studies effectively validated a method by which future studies on a wide variety of 
bacteria could be studied. Using this definition of quorum sensing, [AI-2] can be quickly 
screened for in various bacteria to determine if the species of interest uses AI-2 as a quorum 
sensing signal.  
 
Analytical Methods 
Methods of detection for both AI-2 and AHLs have included bioassays, chromatography, and 
spectrometry.6  Previously, many of the reported studies had focused on genomics and 
proteomics, or the genotypic and phenotypic expression of quorum sensing-dependant 
behaviors such as the observation of bioluminescence in order to detect the presence of 
autoinducers in biological samples. The function of AI-2 and other autoinducers has also been 
studied by constructing and utilizing luxS and other genetic mutants.  
 
Bioassays are used mainly for detection and often rely on reporter strains to obtain 
quantitation.34, 35 Several different methods of detecting and even quantifying AI-2 and AHLs 
have been reported. Up until now, the most widely used method for detecting AI-2 was the V. 
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harveyi bioassay. Quantitation with this method is problematic as this method has a very small 
linear range and is not very reproducible. Other problems with detecting AI-2 are that it has 
many chemical forms, it degrades upon concentration and has no chromophore.  In the case of 
AHL detection, crucial drawbacks of bioassay methods are that sensitivity varies greatly 
between different AHLs, and a different assay is needed for different species of bacteria. 
Although these methods were initially useful in determining the presence of AIs, they are lacking 
in the ability to produce a quantitative understanding of quorum sensing molecules. One of the 
earliest quantitative methods developed was a radioactive assay in which [1-14C]-L-methionine 
is incorporated into production of AHLs via SAM.36 Using this method, relative amounts of AHLs 
can be quantified, however the use of [1-14C]-L-methionine is costly, and this method failed to 
identify all of the AHLs previously reported for the bacteria of interest suggesting a lack of 
sensitivity. Gas chromatography combined with mass spectrometry has also been implemented 
for the identification and quantitation of [AHL].37, 38  
 
High Performance Liquid Chromatography Tandem Mass Spectrometry 
Profiling of AHLs have been completed using LC/MS techniques and have been successful in 
establishing a methodology in which semi-quanititative information can be rapidly produced.39, 40 
While our approach uses similar technology, it ultimately provides direct quantitation that 
combines a number of preferred attributes not previously seen before in the field. Using high 
performance liquid chromatography tandem mass spectrometry (LC-MS/MS) in conjunction with 
selected reaction monitoring (SRM) produces a method that is adequately sensitive, facile and 
universal.  This method was first used for the detection and quantitation of [AI-2] by our lab in 
the V. harveyi and E. coli experiments with good results.41 After separation by liquid 
chromatography, samples can be analyzed by the method of selected reaction monitoring 
events (SRM) on a triple quadrupole mass spectrometer. In this method a precursor ion of m/z 
is selected in the first quadrupole. This parent ion is then fragmented by collisionally-induced 
dissociation (CID) in the second quadrupole, and a characteristic fragment of the ion is selected 
in the third. This allows compounds of the same mass to be separated as well as co-eluting 
compounds. This method is perfectly suited for detection of AHLs as they have two specific 
fragmentations reactions, both of which can be detected by SRM (Scheme 3A). 
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In the case of AI-2, the chemical properties of DPD have made its detection difficult. Our lab has 
designed a method by which DPD is first derivatized (Scheme 3B).41 As a stable quinoxaline, it 
can then be detected with ease by the techniques just described. 
 
Another advantage to the use of these techniques is the availability of metabolomics methods 
previously developed by our laboratory (see Chapter II). If desired, approximately 350 known 
metabolites, at least one from every major biosynthetic pathway, could be detected and 
measured. Being able to monitor concentrations of metabolites would be useful in answering 
questions concerning AI’s role in metabolism because of their links to specific metabolic 
pathways. Major disturbances in important biological pathways could result in changes in 
metabolite concentrations which would be detectable by LC-MS/MS. 
 
(A)
(B)
Scheme 3: Fragmentation reactions of AHLs and derivitizaion of DPD. (A) AHLs can undergo two 
collisionally induced fragmentations while DPD must be first derivitized to the stable quinoxaline  
(DPD-Q) prior to detection (B). 
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Isotope Dilution Tandem Mass Spectrometry 
Quantitative analysis of naturally occurring AI-2 and/or AHL(s) from biological samples is best 
accomplished by addition of isotope labeled internal standards in conjunction with the 
techniques just described. This technique, called isotope dilution mass spectrometry (IDMS), is 
a useful tool for exact quantification due to its high accuracy and sensitivity at low 
concentrations, and eliminates the need to construct an external calibration curve. Isotope 
labeled versions of autoinducers of interest were added to the collected biological samples and 
analyzed by LC-MS/MS techniques described. Difficulties arise with attempts to quantitate 
without the use of isotope labeled internal standards. Differences in factors such as media, 
bacteria, and phases of growth contribute to matrix effects.39 Because isotope dilution involves 
isotopologues of the compound to be analyzed, chemical and biological matrix effects are 
eliminated as both compounds are affected equally. Using SRMs, compounds can be separated 
by mass, and the relative ratio of unlabeled to labeled provides accurate quantitation of the 
natural product.  
 
 
Results and Discussion 
 
To move away from phenotypic observation-based methods, we sought to first profile different 
bacterial strains of interest for AHLs as well as AI-2 and then quantitate their concentrations. 
The backbone of the work presented in this thesis implements the use of LC-MS/MS 
spectrometry techniques to obtain direct quantitation of various natural autoinducers produced 
by multiple bacterial species during normal growth cycles.  Combining the use of stable isotope 
labeled versions of autoinducers and IDMS, we were be able to quantify AI-2 and/or any 
desirable AHL, and through relatively straight forward and well detailed experiments, piece 
together the role that these molecules play in bacterial species that contain quorum sensing 
pathways.  The preferred tools necessary for detection and quantitation include: the synthesis of 
stable isotopically labeled internal standards, and the ability to detect and separate these 
compound by LC-MS/MS techniques. Stemming from the initial V. harveyi and E. coli studies 
conducted by our lab, the work presented in this thesis uses similar methods and protocols with 
slight modification.  A synthesis of 13C-labeled AI-2 has previously been developed.42 Therefore, 
the synthetic work pertaining to this thesis focuses on the development of a method for 
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detecting and quantitating AHLs, although the bacterial species studied were indeed profiled for 
both AI-2 and AHLs. A logical design for the synthesis of doubly deuterated AHLs was proposed 
and completed, and these molecules have been implemented in several biological studies. 
Further, chromatographic and spectrometric techniques for the detection of AI-2 have been 
improved. Methods for AHLs have been developed and refined to the point that future 
experiments can be executed with ease. 
 
Design Rationale for the Synthesis of Stable Isotope Labeled AHLs 
There were several specific goals when we considered the synthesis of stable isotope labeled 
AHLs. In order to easily produce any AHL desirable with minimal steps, the isotope should be 
incorporated in the conserved part of the molecule, in this case, the lactone ring. Additionally, 
the use of two deuteriums, as opposed to the use of one, allows the resulting internal standard 
to be distinguishable from the appearance of a natural 13C isotopomer. The next objective was 
to easily and effectively produce all AHLs by using solid phase synthesis techniques. The 
reason for the use of solid phase chemistry was to increase yields and eliminate the need for 
further purification. Using this technique also enables the synthesis to be biomimetic.  The 
proposed synthesis should have also yielded an enantiomerically pure product, which would 
further reduce the chance of the occurrence of matrix effects leading to invalid measurements. 
Although N-acyl-homoserine lactones have been made previously, most reports have either 
used synthetic C7AHL as reference compound, as it is not thought to be biologically present in 
most systems,38 or incorporated a 13C into the acyl chain.43  A synthesis of tetra-deuterated acyl-
homoserine lactones has been reported44, however this synthesis did not take advantage of 
solid phase techniques, and therefore required extensive purification of both intermediates and 
AHLs. 
 
Synthesis of Deuterated N-Acyl Homoserine Lactones 
In order to implement the chosen method of incorporating any acyl chain into AHLs by use of 
solid phase chemistry, we determined that (S)-[4,4,2H2]-N-Fmoc-methionine 6 would be a useful 
common intermediate. Synthesis of 6 began with protected aspartic acid derivative, 1. This 
molecule was synthesized by a series of known steps.45 Protecting groups were chosen by 
16 
 
ability to survive the basic conditions used in Scheme 4, and the steric bulk of the t-Bu ester 
was critical for the conversion of 1 to 2. Introduction of the isotopes began with converting the 
free acid of 1 with ethylchloroformate to the acyl ethyl carbonic anhydride. This intermediate 
allowed us to selectively reduce the anhydride over the t-Butyl ester using NaBD4 in D2O to give 
2 in 84 % yield.46 Mesylation of the resulting alcohol to (3), followed by a displacement reaction 
with NaSMe gave 4. Global deprotection of 4 with TFA gave 5. In order to introduce this 
molecule to the solid phase using standard solid phase conditions, protection with 9-
Fluorenylmethyl succinimidyl carbonate gave (S)-[4,4,2H2]-N-Fmoc-methionine 6.  
 
 
 
 
 
Scheme 4: Solution phase synthesis of (S)-[4,4,
2
H2]-N-Fmoc-methionine 
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Coupling of 6 to an aminomethyl polystyrene resin was accomplished with 
diisopropylcarbodiimide (DIC), hydroxybenzotriazole (HOBt) and Hünig’s Base (DIPEA) in DMF 
as shown in Scheme 5. The Fmoc goup was then deprotected with 25% piperidine in DMF to 
give 7, followed directly by coupling of the acyl side chain using the same coupling conditions to 
afford 8. Acyl chains that were fully oxidized in the 3 position were protected with an ethylene 
glycol acetal. Protection of the 3OHC4 was unnecessary. Treatment of 8 with 5:2 1M CNBr in 
CHCl3:50% aqueous TFA for 24 hours allowed cyclization to form the homoserine lactone 
moiety and provided cleavage from the resin to give 9 without further purification. In syntheses 
involving acetal protection, cleavage conditions were sufficient for removing the protecting 
group. Although it was originally proposed to obtain enantiomerically pure product, initial results 
proved that racemization occurred readily, and at many points in the reaction scheme. This 
could be attributed to the basic conditions of the coupling reactions. An attempt to modify the 
synthesis and avoid these conditions was carried out. However, it was ultimately decided that 
the elegant nature of the original synthesis outweighed the one downfall of failing to obtain 
enantiomerically pure product. 
  
 
 
 
Scheme 5: Solid phase synthesis of various AHLs 
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Separation and Detection of AHLs and AI-2 
As previously stated, the chemical properties of DPD and its various active forms have made its 
detection problematic. A simple derivatization, developed by our lab,41 allows such 
complications to be avoided. Although it was not an initial focus of this project, a shorter 4 min 
LC-MS/MS method was developed for the quantitation of AI-2. Using this isocratic gradient, the 
throughput for the analysis of biological samples was subsequently increased. Previous 
methods for AHL separation have been long, ranging from ~30-50 minutes.45, 47 Two shorter 
methods have been reported40, although these methods used high column temperatures or 
atypical additives in the mobile phase such as ethylenediaminetetraaceticacid (EDTA).48  These 
conditions are often not suitable for most LC-MS methods. To ensure a high throughput for the 
detection and quantitation of multiple AHLs, a shorter, 7 min, liquid chromatography method 
was developed using a high-efficiency Kinetex core-shell C18 column. The mobile phases used  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Structure, Abbreviations and SRMs for AHLs 
Structure Abbreviation 
SRM 
Parent-fragment 
(m/z-m/z)
 
 
C4 
(D2)C4 
172-102 
174-104 
 
3OHC4 
(D2)3OHC4 
188-102 
190-104 
 
C6 
(D2)C6 
200-102 
202-104 
 
3OC6 
(D2)3OC6 
214-102 
216-104 
 
C7 
(D2)C7 
214-102 
216-104 
 
C8 
(D2)C8 
228-102 
230-104 
 
C10 
(D2)C10 
284-102 
286-104 
 
C12 
(D2)C12 
312-102 
314-104 
(D) indicates position occupied either by a proton or deuterium 
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were 1% acetic acid (AcOH) solution in water and acetonirile (ACN). This provided the 
separation of 8 different AHLs, and most importantly, the separation of the 3OC6 and C7, which 
have the same mass. Table 1 shows the structure, abbreviations and SRMs of each AHL 
analyzed in these studies. Some bacteria only make short chain AHLs, while others make 
longer ones such as C12 and C14 AHLs.  Addition of additives to the mobile phase such as 
EDTA was most likely done to prevent the formation of aggregates that the long hydrophobic 
chains of AHLs can form. To address this issue, 0.1% AcOH was included in the ACN of the 
mobile phase, and the run time was extended to 12.5 min. This slowed analysis but allowed the 
separation of AHLs ranging from C4 to C14 in length (Figure 5).  
 
 
 
 
Figure 5: Chromatographic separation and detection of AHLs. Selected ion chromatograms for the 
(D2)AHLs C4, 3OHC4, C6, 3OC6, C7, C8, C12, C14 showing separation in both the time and mass 
domain. Of importance, the 3OC6 and C7, which have the same mass, are separated by retention 
time. 
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Profiling Bacterial Species for Autoinducer Production 
There are a variety of species of bacteria known to produce AI-1s and AI-2. Table 2 summarizes 
the strains that have been profiled as well as which have been profiled for AHLs and/or AI-2. 
These species were selected for analysis based on whether they possess a LuxS or LuxI 
homologue, availability, as well as the ability to grow them in the lab. Two wild type strains of 
Vibrio fischeri have been profiled for both AI-2 and AHL production. The ainS mutant of Vibrio 
fischeri, CL21, which lacks the ability to produce the C8 AHL as well as VCW2G7, the LuxI 
mutant of ES114 were profiled for AHL production. Again, LuxI is responsible for producing the 
3OC6 AHL; therefore, this mutant lacks the ability to produce the 3OC6 AHL.  Ralstonia pickettii 
(data not shown), Edwarseilla tarda and Yersinia enterocolitica have all been profiled for AI-2 
production. In each of these studies, AI production was monitored as cultures grew from 
exponential to stationary phase. Optical density was taken for each culture to measure growth, 
and cultures were studied with added glucose concentrations of 0, 0.08, 0.14 % (w/v), or a 
combination of these. Measured concentrations of AI-2 and AHLs are denoted as [DPD] and 
[AHL(s)], respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Strains Profiled 
Organism Strain Genotype AI-1s AI-2 
Edwardsiella tarda 15947 WT   
Vibrio fischeri MJ-1 WT   
Vibrio fischeri ES114 WT   
Vibrio fischeri VCW2G7 luxI-   
Vibrio fischeri CL21 ainS-   
Ralstonia pickettii 49129 WT -  
Yersinia enterocolitica 9610 WT   
WT = wild type 
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Results: Vibrio fischeri 
Initial studies were conducted on wild type stains ES114 (Figure 7A), and MJ-1 (Figure 7B) of V. 
fischeri. Concentrations of various AHLs were calculated and plotted to visualize their 
production and degradation. Of particular interest were the identification of two unreported 
AHLs, C6 AHL and C7 AHL. The maximum concentrations of the C6 and C7 AHLs found for 
MJ-1 and ES114 were 0.047 ± 0.005 µM and 0.034 ± 0.007 µM, and 158 ± 1.00 nM and 0.118 ± 
0.013 respectively. Maximum concentrations of 3OC6 AHL and C8 AHL reached 0.287 ± 0.041 
µM and 250 ± 10.00 nM, and 0.00 µM and 2.474 ± 0.211 µM, in MJ-1 and ES114, respectively. 
While probing ES114 and MJ-1 for AHLs, production of AI-2 was also examined as wild type V. 
fischeri is known to produce DPD. Results for ES114 and MJ-1 show an expected increase in 
DPD concentration ([DPD]) during exponential phase with maximum [DPD] reaching 1.79 and 
1.29 µM, respectively. Figure 6 shows all of the autoinducers produced by MJ-1 and ES114. 
Notably, the onset of the production of the C6 and C7 AHLs occurred later in growth during 
stationary phase. In fact, the production of all AHLs in both MJ-1 and ES114 seem to happen 
sequentially with production of every AHL occurring during stationary phase after AI-2 
production has ceased. This was an interesting result as we typically reason that AI production 
will increase as cell numbers are increasing exponentially. This result was unexpected and has 
brought forth further questions about production and utilization of multiple AHLs. Further AHL 
studies were conducted on strains CL21, ainS- mutant, (Figure 7C), and VCW2G7, luxI- mutant, 
(Figure 7d) of V. fischeri. Expected results for CL21 should indicate an absence in the 
production of C8 AHL. Surprisingly, results showed that no other AHL was produced. This could 
be a consequence of the absence of the C8 AHL, if they were indeed produced in a step-wise 
manner. Results for the luxI- mutant indicated that the 3OC6 AHL was not produced in sufficient 
amounts however; the luxI- mutant is a mutant of the ES114 strain of V. fischeri which also 
produces negligible concentrations of the 3-oxo-C6 AHL. Taken together, these preliminary 
studies of V. fischeri have introduced the idea that the production of certain autoinducers in V. 
fischeri may implicate a different means of communication, one not reliant on cell numbers.  
22 
 
 
 
 
 
 
 
 
 
Figure 6: Production of 3OC6, C6, C7 and C8 AHLs in V. fischeri WT strains (A) ES114, and (B) MJ-
1, and V. fischeri mutant strains (C) CL21 and (D) VCW2G7. (E) Growth kinetics of all V. fischeri 
strains studied. 
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Results: Edwardsiella tarda 
Edwardsiella tarda is a gram negative pathogen. This particular species infects fish but is also 
found as a human pathogen.49, 50 E. tarda was profiled for AI-2 production for 24 hours with 
added glucose concentrations of other 0.0% or 0.14% (w/v).  Results showed that [DPD] 
reached a maximum concentration of 34.65 µM and 112.1 µM at 12 and 17 h for the 0% and 
0.14% glucose concentrations, respectively (Figure 8). It was also noted that E. tarda grew at a 
slightly faster rate with the added glucose (Figure 8A). Also, the duration of AI-2 production was 
extended for the culture with added glucose. No detectable concentration of AI-2 was found 
after 15 h for the culture with no added glucose, while AI-2 production continued for an 
additional 5 h in the culture with 0.14% (w/v) glucose (Figure 8B). In both cultures, the 
detectable amounts of [DPD] were found as both cultures entered stationary phase at 
approximately 6 h. 
 
 
 
 
Figure 7: Cascade depictions of all autoinducers produced by V. fischeri strains ES114 and MJ-1. 
Data for AI-2, 3OC6, C6, C7, C8 AHL production in (A) MJ-1 and (B) ES114 
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Characterization of an Enteropathogen 
Yersinia enterocolitica was the second pathogen that was studied. This species is a mammalian 
pathogen,51 and because it belongs to the same genus as Yersinia pestis, otherwise known as 
the plague, it is of particular interest in the research community. Preliminary studies on Y. 
enterocolitica found that this species produced AI-2 in the µM range at a maximum of 
approximately 100 µM, a result not typical in AI-2 quantitation. As a focus, AI-2 production in the 
species Y. enterocolitica was characterized in two different media, and in all four different 
glucose concentrations. In each experiment, all measurements were taken in duplicate. 
 
Results: Yersinia enterocolitica   
Y. enterocolitica was first profiled for AI-2 production in a brain and heart infusion (BHI) media, 
the standard for this species. Y. enterocolitica was profiled for 16 h as it was found in the 
preliminary studies that this species reached stationary phase at approximately 8 h and 
continued to produce DPD until 14 h. Four separate experiments were conducted in duplicate. 
Glucose concentrations of 0, 0.08, 0.14, and 0.20 % (w/v) were added to the media prior to 
inoculation. Growth kinetics were identical for all cultures (Figure 9A). In all of the cultures, DPD 
production began as the cultures began to enter stationary phase and continued for a total of 14 
h. In Y. enterocolitica, [DPD] increased with any concentration of glucose added and a 
Figure 8: Growth kinetics and DPD production in Edwardsiella tarda. Data for cultures spiked with 
either 0.0 ( ), 0.14 ( ) % (w/v) glucose. (A) Growth kinetics measure by OD600. (B) [DPD] 
monitored over 24 hours in each glucose concentration. 
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maximum concentration of 115.12 ± 4.09 µM DPD was found at 12 h. Concentrations of DPD in 
the 0.0 % glucose culture reached a maximum of 78.62 ± 0.24 µM. The maximum [DPD]/OD600 
in all of the glucose concentrations was relatively small range, from 28.75 ± 0.54 µM to 36.54 ± 
0.39 µM (Figure 9B).  Results from the colorimetric glucose oxidation assay revealed that 
glucose levels in each culture dissipated to 0 % over the course of ~2-3 h during the time that 
[DPD] were increasing (Figure 10A-D). These data seemed to indicate that a Y. enterocolitica 
reached a maximum [DPD] with any concentration of added nutrients. Because BHI contains 3 
g glucose per 1 L, it was attempted to repeat these experiments, with the same conditions, in a 
medium that contained low glucose and sugar carbon sources such as LB.  Results, as 
indicated by measurement of OD600 showed that Y. enterocolitica grew similarly in LB as in BHI 
(Figure 11A). When experiments were repeated with identical glucose concentrations, it was 
noted that the [DPD]/OD600 increased both in maximum amount and with time as glucose 
concentrations increased as shown in Figure 11B. Again, DPD production began as Y. 
enterocolitica entered stationary phase. In the 0.0 % (w/v) glucose culture, the [DPD]/OD600 
reached a maximum of 6.391 ± 0.380 µM at 8 h;  the 0.08 % (w/v) glucose culture reached a 
maximum the [DPD]/OD600 of 25.11 ± 2.203 µM at 9 h;  the 0.14 % (w/v) glucose culture 
reached a maximum the [DPD]/OD600 of 28.56 ± 0.069 µM at 10 h; and the 0.08 % (w/v) glucose 
culture reached a maximum the [DPD]/OD600 of 32.92 ± 1.115 µM at 11 h. Two additional 
glucose concentrations were used in the LB studies in an attempt to locate a threshold 
concentration at which Y. enterocolitica would produce a maximum [DPD]. 
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Figure 9: Average growth kinetics and average [DPD]/cell # for Yersinia enterocolitica in BHI. 
Data for culture spiked with either 0.0 ( ), 0.08 ( ), 0.14 ( ), or 0.20 ( ) % (w/v) glucose. 
(A) Average cell density measured by OD600. (B) Average [DPD]/cell # (µM/OD600) measured over 16 
hours for each glucose concentration.  Measurements were performed in duplicate and error bars 
represent the range of data. 
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Figure 10: Average [DPD] and average [glucose] for Yersinia enterocolitica in BHI. Filled markers 
represent [DPD] (µM) and open markers represent % glucose (w/v). Data for cultures spiked with 
either (A) 0.0 ( ), (B) 0.08 ( ), (C) 0.14 ( ), or (D) 0.20 ( ) % (w/v) glucose. All 
measurements were performed in duplicate and error bars represent the range of data. Glucose 
concentrations are represented as total % (w/v) in the culture.   
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Figure 11: Average growth kinetics and average [DPD]/cell # for Yersinia enterocolitica in LB. 
Data for culture spiked with either 0.0 ( ), 0.08 ( ), 0.14 ( ), or 0.20 ( ) % (w/v) glucose. 
(A) Average cell density measured by OD600. (B) Average [DPD]/cell # (µM/OD600) for each glucose 
concentration. All measurements were performed in duplicate and error bars represent the range of 
data. 
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Figure 12: Average [DPD] and average [glucose] for Yersinia enterocolitica in LB. Filled markers 
represent [DPD] (µM) and open markers represent % glucose (w/v). Data for cultures spiked with 
either (A) 0.0 ( ), (B) 0.08 ( ), (C) 0.14 ( ), (D) 0.20 ( ), (E) 0.30 ( ) or (F) 0.50 
( ) % (w/v) glucose. All measurements were performed in duplicate and error bars represent the 
range of data. Glucose concentrations are represented as total % (w/v) in the culture.  
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Methods and Materials 
 
General Methods 
Optical densities were measured on a BioPhotometer (Eppendorf), and all absorbance 
measurements for the colorimetric glucose oxidase assay were performed on a µQUANT 
Universal Microplate Spectrophotometer (Bio-Tek Instruments, Inc.). The liquid 
chromatography-tandem mass spectrometer (LC-MS/MS) used for detection of both AI-2 and 
AHLs consisted of a Thermo Electron Surveyor Autosampler Plus, a Surveyor MS Pump Plus, 
and a TSQ Quantum Discovery Max triple quadrupole MS. All separations were performed on a 
Kinetex reverse phase C18 core-shell column (5 µm pore size, 100 Ǻ particle size, 100 x 2 mm) 
supplied by Phenomenex. All MS spectra were collected and analyzed using the Xcalibur MS v 
2.0.7 software package (Thermo Electron Corporation). All chemicals and solvents were 
purchased from Fisher Scientific, VWR, or Chem Impex and were used without further 
purification. Deuterated solvents used for NMR analysis were purchased from Cambridge 
Isotope Laboratories, Inc. Silica gel (230 x 400 mesh) and TLC plates were purchased from 
Sorbent Technologies. All NMR spectra were recorded on either a Varian Mercury 300 MHz, or 
Varian INOVA 500 MHz spectrometer. All high accuracy mass spectra were taken on a JEOL 
AccuTOF mass spectrometer with a DART ion source. IR spectra were recorded on a Thermo 
Electron Nicolet IR 100 FT-IR. 
 
Bacterial Growth Conditions 
Cultures of Vibrio fischeri wild type strains ES114 and MJ-1, as well as cultures of mutant 
strains CL21 and VCW2G7 were grown aerobically in Luria marine medium (LM)22  at 25 °C with 
shaking. Edwardsiella tarda cultures were grown aerobically in Luria broth (LB)52  at 28 °C with 
shaking. Yersinia enterocolitica cultures were grown aerobically in either LB or Brain Heart 
Infusion (BHI)53  at 28 °C with shaking. 
 
Chromatographic Details  
For all samples, 10 µL was injected onto the column via delivery by autosampler. The column 
temperature was 25 °C. High performance liquid chromatography (HPLC) was performed 
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utilizing a quaternary pump to generate a gradient for the elution of compounds from the 
stationary phase as listed below:    
 
AI-2 
A flow rate of 200 µL/min was used. The mobile phases were 0.1% acetic acid in water (solvent 
A) and HPLC grade acetonitrile (solvent B) and a 4 min isocratic method was created using 5% 
solvent A, and 95% solvent B. 
 
AHL(s) 
A flow rate of 200 µL/min was used. The mobile phases used were 0.1% Acetic Acid in water 
(solvent A) and HPLC grade Acetonitrile (solvent B). These were used to develop the following 
12.5 minute gradient elution profile: t = 0 min, 99% solvent A, 1% solvent B; t = 0.5 min, 95% 
solvent A, 5% solvent B; t = 3 min, 90% solvent A, 10% solvent B; t = 5 min, 25% solvent A, 
75% solvent B; t = 6 min, 25% solvent A, 75% solvent B;  t = 6.5 min, 99% solvent A, 1% 
solvent B; t = 7 min, 99% solvent A, 1% solvent B.   
 
General Mass Spectrometric Detection Parameters for AI-2 and AHLs 
After delivery by HPLC, samples were introduced into the electrospray ionization chamber (ESI) 
through a 0.1 mm diameter fused silica capillary. The voltage for the ESI source was set to 4500 
V. Detection of both AI-2 and AHL(s) occurred in positive mode. Nitrogen was used as the 
sheath gas (40 psi) and the inlet capillary temperature was 290 °C. Argon was used in the 
second quadrupole as the collision gas at a pressure of 1.5 mTorr. Samples were analyzed 
using selected reaction monitoring (SRM) with a scan time set to 0.05 s and a scan width of 1 
m/z.  
 
Measurement of AI-2 Concentration [AI-2] 
In each experiment, the AI-2 concentration ([AI-2]) was measured as cultures grew from 
exponential phase through stationary phase. A preliminary growth curve was constructed in 
order to determine the time needed to reach stationary phase and cell density was measured by 
optical density at 600 nm (OD600). Once determined, the following procedure was used for each 
biological experiment conducted with limited modification necessary. Incubation temperature, 
32 
 
growth medium, and duration of the experiment varied with the bacteria. Cell cultures were 
grown in duplicate. Incubation temperature, growth medium, and duration of the experiment 
varied with the bacteria. Cell cultures were grown in duplicate, unless otherwise noted. Every 
hour, a 300 µL sample was taken from each culture and placed into a 1.5 mL microcentrifuge 
tube containing 10 µL a solution of 13C-DPD (341 µM). The contents were then mixed 
thoroughly by vortexing and centrifuged to remove cells and other particulates. A portion of the 
supernatants (260 µL) were placed in a subsequent microcentrifuge tube containing 26 µL of 
DPD-Tag (5 mg/mL). The contents were allowed to react for 45 minutes before extraction with 
ethyl acetate (2 x 130 µL), followed directly by LC-MS/MS analysis. 
 
Measurement of AHL Concentration(s) [AHL(s)] 
In each experiment, the AHL concentration ([AHL]) was measured as cultures grew from 
exponential phase through stationary phase. A preliminary growth curve was constructed in 
order to determine the time needed to reach stationary phase and cell density was measured by 
OD600. Once determined, the following procedure was used for each biological experiment 
conducted with limited modification necessary. Incubation temperature, growth medium, and 
duration of the experiment varied with the bacteria. Cell cultures were grown in duplicate. Every 
hour, a 300 µL sample was taken from each culture and placed into a 1.5 mL microcentrifuge 
containing 10 µL of a solution of respective deuterated AHLs (6.2 µM). The contents were mixed 
thoroughly by vortexing and centrifuged to remove cells and other particulates. The resulting 
supernatants (260 µL) were extracted two times with half volume of ethyl acetate and 
transferred to 300 µL autosampler vials. If an extraction could not be performed, supernatants 
were taken directly after centrifugation for analysis.  
 
Data Handling for the Calculation of [DPD] 
Data from the SRMs 381-202 and 382-203 (parent-product ion) at a collision energy of 41 eV 
were selected and analyzed by manual integration of chromatographic peak area to obtain 
[DPD]. The SRM 381-202 and 382-203 corresponds to the DPD-Quinoxalines, (12C)DPD-Q and 
(13C)DPD-Q signal respectively. One of two correction factors was applied to integration values 
based on the ratio of (12C)DPD-Q to (13C)DPD-Q signal and are stated below. A full discussion 
of these correction types has been previously reported by our lab.41 
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Correction type 1 is a correction for the naturally occurring (13C)DPD and was applied when the 
ratio of (12C)DPD-Q to (13C)DPD-Q signal was greater than 0.3: 
 
         (   )                      (   )                (   )      
 
Correction type 2 is correction for (12C)DPD impurities in the (13C)DPD internal standard and 
was applied when the ratio of (12C)DPD-Q to (13C)DPD-Q signal was less than 0.2:  
 
         (   )                      (   )                (   )      
 
Using the known [(13C)DPD] added to the culture, following equation was then applied to 
calculate the [DPD]: 
 
       (   )     
       (   )     
     [(   )   ]    [   ]   
 
Data Handling for the Calculation of [AHL(s)] 
Data from the SRMs 202-104, 216-104, 216-104, 230-104 at a collision energy of 11 eV were 
selected and analyzed by manual integration of chromatographic peak area to obtain respective 
[AHL]. The SRMs 202-104, 216-104, 216-104, 230-104 correspond to the C6, 3OC6, C7, and 
C8 AHLs. Using the known [(D2)AHL(s)] added to the culture, the following equation was applied 
to obtain [AHL]: 
 
          
       (  )   
     [(  )   ]    [   ]   
 
No correction was necessary for the observed AHL signals due to the intentional incorporation 
of two deuteriums as previously discussed.  
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Measurement of Glucose Concentration by Colorimetric Glucose Oxidation Assay 
At each time point, a 120 µL sample of culture was taken and placed into an empty 
microcentrifuge tube and centrifuged to remove cell particulates. The supernatants (90 µL) were 
then placed in a separate microcentrifuge tube and immediately stored at -80 °C for analysis for 
the glucose oxidation assay. To obtain glucose concentration at each time point ([glucose]), an 
external calibration curve was first constructed in a 96 well plate by diluting 2 µL of a 40% (w/v) 
glucose solution into 198 µL of DI water followed by two-fold serial dilutions. The set of 
calibration included 0.4, 0.2, 0.1, 0.05 % (w/v) glucose. This calibration curve was then diluted 
1:10 into LB (10 µL into 90 µL LB) in order to accommodate all glucose concentrations in the 
linear range of the assay. If multiple plates were used, one calibration curve from the first was 
diluted into the second for consistency. The calibrations were then used to generate a 
calibration equation by least-squares linear regression of the data. This varied with each plate 
but ranged anywhere from 0.006 to 0.200 %: 
 
                [       ]        
 
This equation was then used to calculate [glucose] at each time point in a given experiment. 
First 10 µL aliquot from each sample was diluted into 90 µL of LB on the same plate as the 
calibration curve. A 200 µL aliquot of a reagent54 containing 0.30 M Tris, 0.36 M NaH2PO42H-
2O, 5.4 M glycerol, 1.0 mM o-dianisidine, 3 kU/L peroxidase an 1 kU/L glucose oxidase type X in 
water was added to both the wells that contained samples and the diluted calibration curve and 
the plate was incubated at 37 °C for 15. At this time, the absorbance at 500 nm was measured, 
and the [glucose] was calculated using the equation generated as described.  
 
N-Boc-(4,4-2H2)homoserine-α-OtBu ester, 2 
To a stirring solution of Boc-Asp-α-OtBu, 1, (5.64 g, 19.49 mmol) and triethylamine (1.97 g, 2.74 
mL, 19.49 mmol) in 50 mL anhydrous THF, at -5 °C, was added Ethyl chloroformate (2.11 g, 
1.87 mL, 19.49 mmol) in 10 mL anhydrous THF via cannula. After stirring continuously at -5 °C 
for 45 min, a precipitate had formed. This precipitate was then filtered, and the filtrate added 
dropwise over 30 min to a stirring solution of NaBD4 (1.63 g, 39.00 mmol) in 15 mL D2O at 10-
12 °C. The reaction was allowed to proceed at room temperature for 4 hours. At this time, the 
solution was acidified with 1 M HCl to pH 2-3. The product was extracted with diethyl ether (3 x 
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80 mL), dried, filtered and concentrated in vacuo to give a yellow oil. The crude product was 
purified by silica chromatography eluted with 7:3 hexanes:ethyl acetate. The purified product, 2, 
(4.27 g, 15.40 mmol) was isolated in 85% yield as a clear oil. 
Rf = 0.49 (1:1 hexanes:ethyl acetate); IR (neat) 3380, 2978, 2098, 1713, 1510, 1366, 1247, 
1161 cm-1; 1H NMR (300 MHz, CDCl3) δ 5.35 (d, J = 7.5 Hz, 1H), 4.42-4.23 (m, 1H), 3.46 (s, 
1H), 2.11 (dd, J = 13.8, 3.1 Hz, 1H), 1.56 - 1.48 (partially under protons at 1.46 ppm, m, 1H), 
1.46 (s, 9H), 1.43 (s, 9H) ppm; 13C NMR (126 MHz, CDCl3) δ 172.00, 156.60, 82.28, 80.30, 
59.16 - 55.74 (m), 50.86, 36.36, 28.25, 27.97 ppm; HRMS-DART (m/z): [M+H]+ calculated for 
C13H24
2H2NO5, 278.19365; found, 278.19338. 
 
N-Boc-(4,4-2H2)homoserine-γ-OMs-α-OtBu ester, 3 
To a solution of 2 (0.902 g, 3.25 mmol), in anhydrous CH2Cl2, at 0 °C, was added triethylamine 
(0.658 g, 0.914 mL, 6.50 mmol) followed immediately by mesyl chloride (0.745 g, 0.507 mL, 
6.50 mmol). After stirring at 0 °C for 2 h, the reaction was allowed to warm to room temperature 
and proceed for an additional 5 h. At this time, the reaction was concentrated in vacuo and 
immediately redissolved in CH2Cl2. This solution was washed with water (3 x 20 mL), and the 
water layers extracted with CH2Cl2 (3 x 20 mL). All organic layers were combined, dried with 
MgSO4, filtered and concentrated in vacuo to give 3 (1.18 g, 3.32 mmol, quant., 80% purity) as a 
yellow oil. This crude product was carried through to the next reaction without purification. An 
analytical sample was purified twice via silica chromatography eluted first with 9:1, 
hexanes:ethyl acetate and second by 100% pentane for ~3 column volumes then 1:1 
pentane:ethyl actetate. The purified product was isolated as a white solid. 
Rf = 0.32 (7:3 hexanes:ethyl acetate); IR (neat) 3381, 2979, 1715, 1513, 1358, 1249, 1166 cm
-1; 
1H NMR (300 MHz, CDCl3) δ 5.16 (s, 1H), 4.28 (d, J = 4.2 Hz, 1H), 3.02 (s, 3H), 2.28 (dd, J = 
14, 2.6 Hz, 1H), 2.03 (dd, J = 14.5, 7.5 Hz, 1H), 1.47 (s, 9H), 1.43 (s, 9H) ppm; 13C NMR (126 
MHz, CDCl3) δ 170.77, 155.35, 82.75, 80.09, 66.51 - 64.29 (m), 50.89, 37.30, 32.02, 28.28, 
27.95 ppm; MS-DART (m/z): [M-Boc+H]+ found, 256.18048. 
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N-Boc-(4,4-2H2)methionine-OtBu ester, 4 
To a stirring solution of 3 (1.18g, 3.29 mmol) in 50 mL 95% ethanol was added a 15% aqueous 
solution of sodium thiomethoxide (2.86 mL, 6.58 mmol). The reaction was allowed to run for 8 h 
at room temperature. At this time, 50 mL of a saturated solution of NH4Cl was added to the 
reaction mixture until a white precipitate formed. The product was the extracted with ethyl 
acetate (3 x 75 mL), and the combined organic layers were dried, filtered and concentrated in 
vacuo to give 4 (0.721 g, 2.87 mmol) in 89% yield and 81% purity. The yellow oil was carried 
through crude to the next reaction. An analytical sample was purified via silica column 
chromatography eluted with 9:1 hexanes:ethyl acetate. 
Rf= 0.68 (7:3 hexanes:ethyl acetate); IR (neat) 3354, 2976, 2928, 1795, 1508, 1541, 1364, 
1248, 1192, 1048 cm-1; 1H NMR (300 MHz, CDCl3) δ 5.12 (d, J =7.9 Hz, 1H), 4.21 (dd, J = 12.5, 
7.5 Hz, 1H), 2.10 - 1.95 (overlapping protons, m, 4H), 1.83 (dd, J = 13.9, 7.5 Hz, 1H), 1.42 (s, 
9H), 1.39 (s, 9H) ppm; 13C NMR (101 MHz, CDCl3) δ 171.35, 155.32, 82.08, 79.73, 53.41, 28.66 
- 30.19 (m), 28.31, 28.00, 15.37; HRMS-DART (m/z): [M+H]+ calculated for C14H26
2H2NO4S, 
308.18646; found, 308.18597. 
 
(4,4-2H2)methionine, 5 
A 1:1 mixture of trifluoroacetic acid (TFA) and CH2Cl2 (14 mL), was added to a flask containing 
4 (0.355 g, 1.15 mmol). After stirring for 5 h the TFA was removed in vacuo to give a brown oil. 
This oil was washed 4 times with CH2Cl2 to remove any additional TFA. Ethyl ether was then 
added to precipitate the product. The resulting white solid was then extracted with water (2 x 10 
mL), and the water layers were washed with ethyl ether (2 x 20 mL). The combined water layers 
were then concentrated in vacuo to give the TFA salt of 5 (0.305 g, 1.15 mmol) in quantitative 
yield as a white solid. The product was carried through as the TFA salt in the next reaction. 
Trituration of the TFA salt of 5 in 95% ethanol solubilized the TFA and any impurities to give the 
pure sample after filtration for analytical analysis.  
mp = 218 °C (decomp.); IR (KBr) 3440, 2952, 2762, 2659, 2106, 1583, 1414, 1338, 1259, 1156 
cm-1; 1H NMR (300 MHz, D2O) δ 3.79 (dd, J = 7.1, 5.4 Hz, 1H), 2.17 - 1.99 (overlapping protons, 
m, 5H); 13C NMR (126 MHz, D2O) δ 174.13, 53.82, 29.41, 27.75 - 28.73 (m), 13.76; HRMS-
DART (m/z): [M+H]+ calculated for C5H10
2H2NO2S, 152.07143; found, 152.07072.  
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N-Fmoc-(4,4-2H2)methionine, 6 
To a stirring solution of the TFA salt of 5 (1.90 g, 7.16 mmol) was added sodium bicarbonate 
(1.20 g, 14.33 mmol) in 60 mL 1:1 acetone:water. After the reaction became homogeneous, 
Fmoc-OSu (N-(9-Fluorenylmethoxycarbonyloxy) succinimide) was added in one portion (2.42 g, 
7.16 mmol). The reaction was allowed to run for 18 h before the acetone was removed by 
evaporation under reduced pressure. The solution was then acidified with 1 M HCl to pH 2. The 
product was extracted with ethyl acetate, and the combined organic layers were dried with 
MgSO4, filtered, and concentrated in vacuo to give 6 (2.54 g, 6.80 mmol) as an off-white solid in 
95% yield and 91% purity. The product could be coupled directly to the solid phase or purified 
via recrystalization from CH2Cl2:hexanes (77% recovery).  
Rf = 0.166 (7:3 hexanes:ethyl acetate); mp = 144-146 °C; IR (neat) 3321, 3050, 1524, 1447, 
1334, 1263, 1056, 746 cm-1; 1H NMR (500 MHz, CDCl3) δ 7.77 (d, J = 7.5 Hz, 2H), 7.60 (s, 2H), 
7.41 (t, J = 7.5 Hz, 2H), 7.32 (t, J = 7.5 Hz, 2H), 5.45 (d, J = 7.6 Hz, 1H), 4.64 - 4.49 (m, 1H), 
4.45 (d, J = 6.7 Hz, 2H), 4.24 (t, J = 6.8 Hz, 1H), 2.22 (dd, J = 13.8, 4.0 Hz, 1H), 2.11 (s, 3H), 
2.01 (dd, J = 14.0, 7.9 Hz, 1H) ppm; 13C NMR (101 MHz, CDCl3) δ 176.02, 156.12, 143.69, 
141.36, 127.78, 127.11, 125.02, 120.03, 67.19, 52.94, 47.17, 31.27, 15.32; HRMS-DART (m/z); 
[M+H]+ calculated for C20H20
2H2NO4S, 374.13951; found, 374.13825. 
 
Representative N-Fmoc-(4,4-2H2)methionine resin loading protocol 
Amino methyl polystyrene resin (0.100 g, 0.110 mmol) was placed into a 5 mL peptide vessel 
and washed with DMF, H2O, EtOH, Acetone and CH2Cl2. Approximately 10 mL of each solvent 
was used for each washing, and the vessel was agitated for ~5 s for each washing to ensure 
removal of the prior solvent. To swell the resin after washing, 1 mL of CH2Cl2 was added to the 
vessel. In a vial, an activated solution of N-Fmoc-(4,4-2H2)methionine, 6, (0.163 g, 0.440 mmol), 
1-hydroxybenzotriazole (HOBT), (0.017 g, 0.110 mmol), N,N-diisopropylcarbodiimide (DIC), 
(0.069 g, 0.440 mmol), and diisopropylethylamine (DIPEA), (0.095 g, 0.550 mmol) was prepared 
in 2 mL DMF. After the activated solution sat at room temperature for 15 min, it was added to 
the peptide vessel containing the resin. The resulting reaction mixture was then shaken for 2 h 
at room temperature.  The resin was filtered and washed using the procedure described above. 
This material was then stored and used to synthesize various 2H2 AHLs as needed. 
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Representative synthesis of (2H2) AHLs, N-octanoyl-(4,4-
2H2) acylhomoserine lactone 
In a standard peptide vessel containing the resin supported N-Fmoc-(4,4-2H2)methionine, 6, was 
added 4 mL of a 25% piperidine solution in DMF. This reaction mixture was allowed to shake at 
room temperature for 1 h. The resin was then filtered and washed using the washing procedure 
described above. A solution of octanoic acid (0.087 mL, 0.550 mmol), HOBT (0.017 g, 0.110 
mmol), DIC (0.069 g, 0.440 mmol), and DIPEA (0.069 g, 0.550 mmol) was prepared in a 
separate flask in 3 mL DMF. This activated solution was allowed to sit for 15 min at room 
temperature. At this time, the activated coupling solution was added to the peptide vessel 
containing the now deprotected 6. This reaction mixture was allowed to shake for 18 h at room 
temperature. At this time, the resin was filtered and washed as previously described for the 
resin loading protocol. The washed resin was then left on the filter to dry for 2 h before being 
transferred to a 20 mL where1.67 mL of 1M CNBr in CHCl3, 0.330 mL H2O and 0.330 mL TFA 
were added. This reaction was allowed to stir at room temperature for 24 h, after which the resin 
was again filtered and washed with CHCl3 ( 3 x 5 mL). The filtrate was then collected and 
concentrated in vacuo to give the crude N-octanoyl-(4,4-2H2) acylhomoserine lactone as a 
yellow oil. The oil was then redissolved in 15 mL CH2Cl2 and washed with water (3 x 15 mL). 
The organic layer was then dried with MgSO4 and concentrated in vacuo to give N-hexanoyl-
(4,4-2H2) acylhomoserine lactone, (
2H2)C8 AHL, (0.0109 g, 0.0475 mmol) as a white solid in 
49% yield and >95% purity. All other AHLs can be synthesized using this procedure and the 
data for each of the other 7 (D2)AHLs synthesized are listed below. 
1H NMR (300 MHz, CDCl3) δ 6.09 (d, J = 4.9 Hz, 1H), 4.55 (ddd, J = 11.6, 8.6, 5.7 Hz, 1H), 2.83 
(dd, J = 12.5, 8.6 Hz, 1H), 2.29 - 2.29 (m, 2H), 2.11 (t, 12.1 Hz, 1H), 1.71 - 1.56 (m, 2H), 1.28 
(dt, J = 9.2, 4.6 Hz, 8H), 0.87 (t, J = 6.7 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 175.57, 173.77, 
67.34 – 63.46 (m), 49.24, 36.20, 31.64, 30.42, 29.16, 28.96, 25.43, 22.58, 14.04; HRMS-DART 
(m/z): [M+H]+ calculated for C16H28
2H2NO3, 286.23512; found, 286.23441. 
 
(D2)C4 
1H NMR (500 MHz, CDCl3) δ 5.99 (s, 1H), 4.56 (ddd, J = 11.6, 8.6, 5.7, Hz, 1H), 2.88 (dd, J = 
12.5, 8.6 Hz, 1H), 2.25 (td, J = 7.4, 2.1 Hz, 2H), 2.13 (t, J = 12.1 Hz, 1H), 1.80 - 1.64 (m, 2H), 
0.98 (t, J = 7.4 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 175.48, 173.53, 66.86 - 64.22 (m), 49.27, 
38.05, 30.50, 18.87, 13.68; HRMS-DART (m/z): [M+H+] calculated for C8H14
2H2NO3, 174.10992; 
found, 174.10910. 
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(D2)3OHC4 
1H NMR (300 MHz, D2O) δ 4.66 (dd, J = 20.4, 10.9 Hz, 1H), 4.27 - 4.11 (m, 1H), 2.66 - 2.54 (m, 
1H), 2.45 (d, J = 6.6 Hz, 2H), 2.32 (td, J = 12.2, 5.1 Hz, 1H), 1.21 (d, J = 6.3 Hz, 3H); 13C NMR 
(126 MHz, D2O) δ 178.47, 173.92, 64.78, 49.08, 44.38, 27.47, 21.76; HRMS-DART (m/z): 
[M+H+] calculated for C8H12
2H2NO4, 190.10484; found, 190.10444.   
 
(D2)C6 
1H NMR (500 MHz, CDCl3) δ 6.02 (s, 1H), 4.55 (ddd, J = 11.6, 8.6, 5.8 Hz, 1H), 2.86 (dd, J = 
12.5, 8.6 Hz, 1H), 2.26 (td, J = 7.4, 1.5 Hz, 2H), 2.12 (t, J = 12.0 Hz, 1H), 1.66 (dt, J = 15.1, 7.6 
Hz, 2H), 1.33 (dd, J = 7.2, 3.8 Hz, 4H), 0.91 (t, J = 7.1 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 
175.48, 173.70, 49.27, 36.15, 31.34, 30.49, 25.09, 22.34, 13.88; HRMS-DART (m/z): [M+H+] 
calculated for C10H14
2H2NO3, 202.14122; found, 202.14083. 
 
(D2)3OC6 
1H NMR (300 MHz, CDCl3) δ 7.67 (s, 1H), 4.59 (ddd, J = 11.5, 8.8, 6.6 Hz, 1H), 3.46 (s, 2H), 
2.74 (dd, J = 12.5, 8.8 Hz, 1H), 2.51 (t, J = 7.3 Hz, 2H) 2.22 (t, J = 12.0 Hz, 1H), 1.70 - 1.54 (m, 
2H), 0.98 - 0.89 (m, 3H); 13C NMR (126 MHz, CDCl3) δ 206.42, 174.72, 166.26, 67.15 - 62.44 
(m), 49.04, 48.04, 45.77, 29.65, 16.83, 13.50; HRMS-DART (m/z): [M+H+] calculated for 
C10H14
2H2NO4, 216.12049; found, 216.12074. 
 
(D2)C7 
1H NMR (300 MHz, CDCl3) δ 5.98 (s, 1H), 4.54 (ddd, J = 11.6, 8.6, 5.7 Hz, 1H), 2.85 (dd, J = 
12.5, 8.6 Hz, 1H), 2.28 - 2.21 (m, 2H), 2.11 (t, J = 12.1 Hz, 1H), 1.64 (dt, J = 15.2, 7.7 Hz, 2H), 
1.39 - 1.20 (m, 6H), 0.88 (dd, J = 9.0, 4.6 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 175.53, 173.73, 
66.80 - 64.01 (m), 49.26, 36.19, 31.47, 30.48, 28.86, 25.38, 22.47, 14.02; HRMS-DART (m/z): 
[M+H+] calculated for C11H18
2H2NO3, 216.15687; found, 216.15664. 
 
(D2)C12 
1H NMR (500 MHz, CDCl3) δ 6.01 (d, J = 4.3 Hz, 1H), 4.55 (ddd, J = 11.6, 8.6, 5.7 Hz, 1H), 2.86 
(dd, J = 12.5, 8.6 Hz, 1H), 2.25 (td, J = 7.4, 1.5 Hz, 1H), 1.65 (dt, J = 15.0, 7.6 Hz, 2H), 1.37 - 
1.20 (m, 16H), 0.89 (t, J = 7.0 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 175.51, 173.73, 68.01 - 
62.44 (m), 49.26, 36.20, 31.89, 30.48, 29.59, 29.44, 29.32, 29.30, 25.43, 22.67, 14.10; HRMS-
DART (m/z): [M+H+] calculated for C16H28
2H2NO3, 286.23512; found, 186.23441. 
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(D2)C14 
1H NMR (500 MHz, CDCl3) δ 6.03 (d, J = 4.8 Hz, 1H), 4.55 (ddd, J = 11.6, 8.6, 5.8 Hz, 1H), 2.86 
(dd, J = 12.5, 8.6 Hz, 1H), 2.25 (td, J = 7.3, 1.4 Hz, 2H), 2.12 (t, J = 12.1 Hz, 1H), 1.65 (dt, 15.0, 
7.6 Hz, 2H), 1.39 - 1.19 (M, 20H), 0.98 (t, J = 7.0 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 175.53, 
173.74, 68.60 - 63.18 (m), 49.25, 36.20, 31.91, 30.45, 29.66, 29.63, 29.45, 29.31, 29.21, 25.43, 
22.68, 14.11; HRMS-DART (m/z): [M+H+] calculated for C18H32
2H2NO3, 314.26642; found, 
314.26532. 
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Chapter II 
Determining Metabolic Profiles of Rat Insulinoma Cells 
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A version of this chapter was originally published by J. Jason Collier, Susan J. Burke, Mary E. 
Eisenhauer, Danhong Lu, Renee C. Sapp, Carlie J. Frydman, and Shawn R. Campagna: 
 
 Collier JJ, Burke SJ, Eisenhauer ME, Lu D, Sapp RC, et al. (2011) Pancreatic β-Cell 
Death in Response to Pro-Inflammatory Cytokines Is Distinct from Genuine Apoptosis. PLoS 
ONE 6(7): e22485. doi:10.1371/journal.pone.0022485 
 
The results and discussion, and methods and materials sections of the following chapter can be 
found in the stated publication with no revisions as the author has been credited as a writer, 
researcher, and analyzer for these sections. Results that were obtained by credited co-
researchers are clearly defined within the text.  
 
Abstract 
 
Type 1 Diabetes mellitus (T1DM) occurs in response to the autoimmune destruction of insulin 
producing β-cells of the pancreas. It has been proposed that the method of β-cell death 
proceeds by one of two mechanisms, necrosis or apoptosis, and that these mechanisms are 
independent of each other and that one will prevail over the other preferentially.  Until now, 
T1DM has been studied mainly by genomic and proteomics techniques. While these techniques 
are the standard in this field of research, a chemical approach, particularly at the level of 
metabolism provides a better representation of what is happening in a system in real time. The 
technological platform that addresses the metabolism of a given system is called metabolomics. 
Often, metabolism will change in response to toxins or disease; the study of these systems in 
response to a stimulus is one useful application of metabolomics. Here, a targeted 
metabolomics mass spectrometry approach was employed to measure the metabolome of rat 
islet β-cells that were exposed to inducers of cell death. This method was then used to 
determine a metabolic profile for the two proposed mechanisms of β-cell death. Approximately 
90 metabolites were observed that demonstrated statistically reliable and valid changes when 
compared to a control group. In the profiles generated, several key differences were noted that 
corresponded with supporting or previous findings. As a result, these findings provided evidence 
that these stimuli not only resulted in a reduction in cell viability, but the metabolic profiles were 
additionally distinct from one another. 
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Background and Significance 
 
In the past 10 years, systems biology has grown in regards to technological platforms in which 
systems can be explored and the data interpreted on the molecular level, with the emergence of 
metabolomics being the newest of these platforms.55 The ability to accurately detect, identify 
and quantitate the metabolites present in living organisms can provide a wealth of information 
that complements other technologies such as genomics and proteomics in a variety of 
biologically relevant applications.56-58 The analysis of molecular metabolism can be an effective 
method to evaluate the state of a system. In the “omics” cascade, metabolism represents what 
is actually happening in an organism after genes have been regulated, expressed as 
phenotypes and finally modified post-transcriptionally. Further, it can be probed in systems 
where stress of various forms has been applied. This chapter focuses on one of those 
applications. T1DM is known to be caused by the reduction of insulin producing β-cells in the 
Langerhans of the pancreas due to the death of these cells.59  Insulin deficiency then causes 
increased blood glucose along with a multitude of symptoms that must be treated. Currently, 
treatments of the disease usually include insulin injections, as there is no known cure for T1DM. 
While it is known that β-cell death is a hallmark for T1DM, how these cells die, as well as why 
they are specifically selected for destruction, remains largely unknown. Two mechanisms of cell 
death have been proposed, although these have been debated. Conceivably, clarification as to 
which mechanism, if either, is responsible for β-cell death will advance discussions of possible 
treatments or cures for T1DM. Here, a mass spectrometry based metabolomics approach was 
used to determine metabolic profiles for rat insulinoma cells treated with cell death inducers, in 
an effort to explore mechanisms of cell death on a chemical level.  
 
Metabolomics Background 
Biologists rely on a number of analytical techniques to study the often complex systems of living 
organisms. Starting at the genotypic level, there is what is described as the “omics” cascade 
that consists of all the technology from which systems biology research is conducted. The 
newest discipline to emerge is also closest to the phenotypic level and deals with the 
metabolome.58 The metabolome refers to the set of all small molecule metabolites found in a 
biological sample, and the technological platform has been termed metabolomics. Currently, 
there is no single platform for the complete analysis of all the metabolites present in a single 
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system; however, over the past 10 years there have been an increasing number of papers 
published that use metabolomics as a bioanalytical technique, demonstrating its usefulness as a 
bioanalytical tool.60, 61 One possible reason that metabolomics has lagged behind other 
techniques such as genomics and proteomics is that the metabolome is often dynamic and 
complex. There are an estimated 2,000 major metabolites in mammalian organisms and up to 
~200,000 in the plant kingdom, and these compounds represent a broad variety of chemical 
classes with different chemical properties.60 Metabolite pools can change on the order of 
seconds, and even slight environmental changes, such as a minor temperature change, can 
result in changes in the metabolome. Despite the challenges associated with metabolomics, one 
can easily recognize its benefits. Metabolism gives an accurate and timely view of the state of 
the system and is often associated with the overall well-being of the organism or cell.  
 
Metabolic Profiling vs. Metabolic Fingerprinting 
The two major approaches to metabolomics include metabolic profiling and metabolic 
fingerprinting. In most cases, metabolic profiling refers to the analysis of a certain group of 
metabolites that is usually hypothesis driven and quantitative, also called a targeted analysis. 
An example would be the analysis of fatty acids in a mammalian tissue. An even more specific 
application is the selection of specific compounds for identification that may serve as biomarkers 
of a disease or toxin exposure. This type of targeted analysis can be useful in supporting the 
data collected from other technical “omics” platforms. Conversely, metabolic fingerprinting is the 
global analysis of samples with the intent to obtain a characteristic metabolite pattern or 
“fingerprint” and therefore, inherently an untargeted approach. This application is useful in 
showing the overall change in metabolism in response to a treatment or alteration such as 
genetic manipulations. Regardless of the sample or application, the steps leading to a 
metabolomics data set are the same: sample collection, extraction, chemical analysis, and data 
analysis.  
 
Sample Type 
Clinical applications of metabolomics have been useful in the field of human biology, where 
fluids, such as serums and urine, can be quickly analyzed for changes in metabolic profiles in 
response to disease, diet, toxins etc.62 This application, however, only provides information on 
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the metabolism of the organism as a whole, which usually provides no quantitative information, 
and can also result in the introduction of additional variables. When dealing with individual cell 
types, variables such as gender, environmental exposures, and contributions from different 
tissues, essentially become non-existent due to the fact that the sample is often derived from a 
controllable cell line as opposed to a human or animal model.60  
 
Sampling and Extracting 
The sampling in a metabolomics experiment should be determined by the experimental design 
and type. In any case, the best results are obtained when the following are taken into 
consideration: replication and quality control. Inter-day and multiple-day replications should be 
taken in order to reduce biological variability. Additionally, the appropriate use of control 
samples and/or internal standards can greatly enhance the statistical validity of the data set. 
Once an experiment has been designed and the samples have been acquired, they must be 
handled with extreme care as to not cause any disturbances in the existing metabolome. Often 
this requires the use of cold temperatures to suspend metabolism. Some techniques used 
include flash freezing, freeze clamping or immediate quenching. In cases where the 
metabolome is not immediately extracted, the sample should be kept cold and the length of time 
before extraction should be kept constant between all samples. The extraction technique will 
vary with the experiment, but careful measures should be taken to ensure that all parameters of 
a given experiment remain the same for all samples to be analyzed once an extraction 
technique has been validated. Usually, the metabolome is extracted in order to separate the 
metabolites from the complex biological matrices in which they are found, however direct 
injection is one method of sample preparation. The extraction solvent should be suitable for the 
type of sample. For example, a cold methanolic solution is usually used for mammalian tissue, 
whereas more complex solvents, such as acidic acetonitrile mixtures, are typically used for 
bacterial cultures.63 Here, the use of an internal standard spike can provide another means by 
which the data set can be validated. It should be noted that in no experiment will the whole 
metabolome remain intact. The very nature of the sample preparation step will guarantee that 
some metabolites will be lost due to the fact that not all metabolites can be extracted by one 
method.  
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Analytical Methods 
After the sample has been collected and extracted, the final stages in a metabolomics 
experiment are the analyses of the metabolites which include: separation, detection, and if 
possible, quantification. Some of the requirements for obtaining scientifically relevant 
metabolomics data are that the instruments used for analysis have excellent sensitivity and 
resolution for a wide range of molecules, the ability to work with a variable range of metabolite 
concentrations, relatively short analysis times, and reasonable reproducibility. Currently, the two 
most widely used methods for metabolic analysis are nuclear magnetic resonance (NMR), and 
mass spectrometry (MS). Both have their own particular advantages and disadvantages. With 
NMR, samples require minimal preparation which preserves the sample.64, 65 NMR also offers 
the ability to directly quantitate the relative abundance of metabolites in a sample, which can be 
difficult to do with MS.  
 
Mass Spectrometry Based Metabolomics 
MS has come to the forefront of metabolomics research since becoming a successful tool in 
drug metabolite analysis.61 The application of modern MS to cell culture metabolism is 
particularly useful because of its high sensitivity and possibility for metabolite quantitation. 
Several variations of MS have been implemented to study metabolism.61, 66, 67 One of the 
simplest, direct injection has been useful for samples with sufficient metabolite content and 
concentrations, such as urine. The major drawback of this method is that the biological matrix in 
which the sample is located will usually reduce signal quality. Another problem associated with 
direct injection is the difficulty when attempting to distinguish between analytes of the same 
mass-to-charge ratio (m/z). When working with cell cultures, additional steps, such as the 
incorporation of chromatography, are typically required for the analysis of global metabolism. 
Variations such as gas chromatography mass spectrometry (GC-MS) and liquid 
chromatography mass spectrometry (LC-MS) are often used in order to increase the number of 
metabolites seen, however because of the complexity often involved with sample preparation in 
GC-MS, LC-MS has taken a leading role in most MS metabolomics research.68 Considerations 
when choosing a LC-MS method include 1) separation of the metabolites from the biological 
matrix, 2) separation using chromatography, 3) analyte ionization, 4) detection of the fragment 
and 5) identification. Again, separation of the metabolome from the matrix as well as using 
chromatography is important for the overall signal quality.  Reduction of the number of analytes 
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at a given time reduces the occurrence of ion suppression, and provides another level of 
specificity. The ionization method most widely used for metabolomics has been electrospray 
ionization (ESI). ESI is a soft ionization technique that ionizes liquid samples directly into the 
gas phase, which is well suited for LC-MS. The number of metabolites measured increases 
when both positive and negative ion modes are used. Metabolites such as amines will ionize 
best in positive ion mode while acidic metabolites such as phosphates will ionize better in 
negative mode. The two most common mass analyzers used in metabolomics directed research 
are time-of-flight (TOF) and quadrupole analyzers.67  As mentioned in the previous chapter, the 
preferred MS method used by our lab is detection by selected reaction monitoring (SRM) on a 
triple quadrupole mass spectrometer. Coupled with separation by high performance liquid 
chromatography (HPLC), this method has the sensitivity and selectivity required to detect up to 
~350 polar metabolites as developed by Rabinowitz and co-workers. The target experiments 
that will use this method will require that both the parent and product mass be known however, 
a library of the ~350 metabolites was also created by Rabinowitz using chemical standards that 
will be used in the studies presented in this chapter. 
 
Data Analysis 
The data sets generated by MS metabolomics techniques are often large and complex. The first 
challenge encountered after data collection is the organization of these data into similar classes 
by correctly identifying each individual metabolite.69 Often, the differences in metabolite pools 
are of interest so it is imperative that metabolites are identified correctly. The use of chemical 
standards and databases can greatly enhance identification, although these tools are still in the 
beginning stages of development.70, 71 72 Software for the identification and selection of 
chromatographic peaks has been important for evaluation of untargeted metabolomics data 
sets.67 Once the metabolite has been identified, certain normalization factors will often be 
applied to the raw data in order to correct for variability in the experiment. Once these have 
been applied, the final task is to assemble the data for visualization.  
 
Pancreatic β-cell Death 
T1DM is an autoimmune disease that is characterized as the loss of the beta-cell mass of the 
islets of the Langerhans in the pancreas that results in insulin deficiency.59 Pro-inflammatory 
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cytokines, such as interleukin-1β (IL-1β) and gamma-interferon (γ-IFN), induce the expression of 
genes that produce inflammatory mediators, such as nitric oxide synthase (iNOS), and the 
production and accumulation of nitric oxide (NO) inside the cell will inevitably decrease β-cell 
viability.73, 74 While it is known that the secretion of pro-inflammatory cytokines play a role in β-
cell death, the initial cause and the precise method by which β-cells are destroyed are not fully 
understood. Two mechanisms of cell death that are generally accepted, yet debated, are an 
apoptotic pathway75, 76and/or a necrotic pathway.77, 78 Pro-inflammatory cytokines could induce 
either of these pathways through a common bcl-2 inhibitory pathway, which makes discerning 
the direct cause of β-cell death problematic.79 Apoptosis is a programmed form of cell death that 
causes morphological changes in the cell which lead to irreversible damage.80  It is known to be 
activated by a cascade of different caspases. With regards to β-cell death, initiation of the 
apoptoside cascade results in targeted degradation of intracellular proteins that lead to cellular 
death. When cleaved, one of these caspases, Caspase 3 (CASP3), is responsible for the 
targeted destruction of intracellular proteins that lead to cell death.81 CASP3 activity is a known 
marker for apoptosis mediated cell death. The pathways of non-apoptosis forms of cell death, 
such as necrosis are even less understood.  
 
There are several different models in which T1DM has been studied. The first animal model for 
diabetes research was the non-obese diabetic (NOD) mouse model. Developed in 1970, this 
strain sed develops the autoimmune disease spontaneously, similar to human T1DM.82 Even 
with this model, the exact cellular mechanism behind β-cell death is unknown; the complexity of 
the pathways involved in several different rat modeling systems has added confusion as to 
which, if any of these pathways is actually involved in human T1DM.  
 
Pancreatic β-cell Death is likely the Result of a Non-Apoptotic Mechanism 
In a series of studies, pro- and anti-apoptotic proteins were subject to manipulation in order to 
test the hypothesis that if apoptosis is indeed the primary pathway involved in β-cell death, then 
exposure to cytokines known to be involved in a non-apoptotic method of cell death should be 
protected the cell from damage.77 Several methods were implemented in order to first show that 
apoptosis was not occurring in cells exposed to pro-inflammatory cytokines. First, the effects of 
cytokines interleukin-1beta (IL-1β) and gamma-interferon (γ-IFN) were compared with the 
effects of a known apoptosis inducer, camptothecin, in both a normal cytokine sensitive cell line 
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(832/13) and a cell line selected for cytokine resistance (833/15).83 Results indicated a 40% 
decrease in viability in the 832/13 cell line when exposed to cytokines, and an identical 80% 
decrease in viability in both cell lines with exposure to camptothecin This showed that selectivity 
for cytokine resistance protected against death by exposure to the cytokines, but offered no 
protection against exposure to apoptosis induced cell death. Next the 832/13 cell line was 
subjected to overexpression of the anti-apoptotic protein kinase Akt1. This provided protection 
against cell death when the cells were treated with camptothecin, but not with cytokines. 
Additionally, siRNA mediated suppression of the proapoptotic protein Bax enhanced cell viability 
in those treated with apoptosis inducers, but provided no protection in cells treated with 
cytokines. In apoptosis, CASP3 activity can be measured via radioimmunoassay, and it was 
verified that camptothecin induced CASP3 cleavage in both cell lines as well as isolated primary 
cells. In contrast, NO is known to prevent caspase activity84; this was consistent with the finding 
that no increase in CASP3 activity occurred in these cell lines treated with pro-inflammatory 
cytokines. Another marker of apoptotic cell death, annexin V staining, was used, and results 
again showed that camptothecin and not IL-1β and γ-IFN caused increases in staining. Finally, 
intracellular ATP levels were examined. It has been suggested that ATP levels could be an 
important biomarker for a switch from necrosis to apoptosis. Caspase activity requires energy, 
and so it is presumed that intracellular ATP will be higher if apoptosis is occurring while ATP 
levels will drop if a switch to a non-apoptosis pathway has occurred.85 Results in these studies 
indeed showed that ATP levels increased in both sensitive and resistant cell lines treated with 
camptothecin, while IL-1β and γ-IFN decreased ATP levels in the sensitive cell line 832/13 and 
had no effect on the intracellular levels of ATP in the cytokine resistant cell line 833/15. Taken 
together, these studies clearly support the idea that pro-inflammatory cytokine mediated β-cell 
death proceeds by a mechanism independent and distinct from those known to occur in 
apoptotic mediated pathways. It should be noted that previous reports with contradictory results 
failed to employ a control for apoptosis such as a genuine apoptosis inducer.86, 87  Several 
biomarkers are proven to be useful when attempting to distinguish between the two proposed 
pathways. Therefore, we intended to study the metabolome of rat insulinoma cells which had 
been exposed to either pro-inflammotory cytokines or known apoptosis inducers. If the 
information obtained from the metabolome were consistent with the previous findings, then cell 
lines treated with known apoptotic inducers should show differences in metabolites when 
contrasted with cell lines treated with pro-inflammatory cytokines.   
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Results and Discussion 
 
The unique intersection of the strategies previously employed by the Collier lab and mass 
spectrometry based metabolomics developed by our lab aimed to further support the findings 
that a non-apoptosis pathway is predominate in rat islet cells. The initial goal was to develop an 
extraction method to analyze the metabolome of rat islet cells from two different cell lines. Given 
that this type of analysis has never been initiated in any islet cell line, it was unknown as to 
whether this method would ultimately provide any metabolic information. A preliminary 
extraction was done using a typical mammalian tissue protocol63, and the supernatants 
analyzed via liquid chromatography tandem mass spectrometry (LC-MS/MS) in SRM mode. 
Results indicated the extraction performed and method of analysis was suitable for the islet 
cells, so a series of studies was conducted on islet cells of various treatments. The treatments 
used were specifically selected in order to compare the metabolic differences in islet cells where 
apoptosis was induced versus cytokine exposure. This preliminary hypothesis presumes that 
these two cellular mechanisms are independent and involve discretely separate metabolic 
pathways, and therefore metabolic profiling of cells undergoing these two different mechanisms 
of cell death will reveal differences in metabolite pools.  
 
Distinction between Cell Death via Exposure to Pro-inflammatory Cytokines versus 
Genuine Apoptosis Inducers  
In a second series of studies conducted by the Collier lab, the hypothesis that pro-inflammatory 
cytokines and apoptosis inducers differed in the mechanism by which cell death occurs was 
further explored. In an effort to prove that the cytokine sensitive cell line 832/13 used in these 
and past studies was just as sensitive to cytokine and apoptosis mediated killing as other cell 
lines used in contradictory studies,88 an INS-1E derived cell line was first tested for viability 
when exposed to both. It was found that both cell lines were equally sensitive to both inducers. 
In order to further support the hypothesis that cytokine mediated cell death proceeds by a 
different mechanism than apoptosis, key components from known pathways of each mechanism 
were manipulated and tested for viability in response to both IL-1β and γ-IFN and camptothecin. 
Manipulation of apoptosome by siRNA-mediated suppression of APAF-1 or a dominant-negative 
form of capsase-9, protected against killing by camptothecin but not IL-1β and γ-IFN.  Inhibition 
of IKKβ, a known component of the NF-kB signaling pathway, by pharmacological inhibitor 
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TPCA or overexpression of an IκBα super repressor, blunted cytokine inducer NO production 
and provided protection against losses in β-cell viability. No protection against camptothecin 
mediated apoptosis was observed with either method.  
 
Metabolic Profiling by Tandem Mass Spectrometry  
From here, the metabolome of 832/13 rat islet cells treated separately with either 
proinflammatory cytokines (IL-1β and γ-IFN), or an apoptosis inducer (camptothecin) was first 
extracted, and then analyzed using the previously validated LC-MS/MS technique.89, 90 Again, 
stemming from the previous findings, it was hypothesized that the metabolic profiling of the 
differently treated cell lines would reveal differences in some metabolite pools and no 
differences in others because the two different methods of β-cell death would be using different 
metabolic pathways; cytokines induce cell death by increasing levels of intracellular NO into the 
µM range, while apoptosis induces DNA damage through the caspase cascade.  To show these 
differences, fold changes in both treatments relative to a non-treated 832/13 cell sample were 
considered. Figure 14 is a representative heatmap that displays these fold changes. 
Approximately 130 metabolites were measured in positive mode and 175 were measured in 
negative mode. Of these, 90 metabolites were verified to have changed with respect to the 
control samples.  Additionally, a table of p-values was constructed in order to determine the 
probability that the differences seen in the treated cells relative to the non-treated cells were 
indeed due to addition of the treatment (Tables 30 and 31, Appendix). In both cases, distinct 
metabolic profiles were seen. However, it should be noted that although the concentration of 
most metabolites in both the IL-1β and γ-IFN and camptothecin treated cells increase, this does 
not necessarily indicate that these cells are more metabolically active than the control cells. 
Metabolism changes can both be the result of a build-up of a metabolite or an increased use of 
a metabolite, and it is impossible to distinguish between the causes of these changes in pool 
size measurements, unless flux experiments are conducted. Regardless, obvious differences in 
the metabolic response to the two different treatments were observed. One of the most notable 
changes was the 400-fold increase in citrulline in cells treated with IL-1β and γ-IFN.  Citrulline is 
an end product of the iNOS reaction, and these results support the previous findings that NO 
levels increase in cells treated with IL-1β and γ-IFN.  
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IL -1β + γ-IFN   :   camptothecin
Figure 14: Representative heatmap displaying metabolite fold changes relative to a control. Values 
are given in log2, so that “3.00” is a minimum of an 8-fold increase, while “-3.00” is a minimum of an 8-
fold decrease. Red indicates a metabolite increase in the treatment condition relative to an untreated 
control, while green represents a decrease relative to control. 
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Methods and Materials 
 
General Methods 
The LC-MS/MS system used for detection of metabolites consisted of a Thermo Electron 
Surveyor Autosampler Plus, a Surveyor MS Pump Plus, and a TSQ Quantum Discovery Max 
triple quadrupole MS. All MS spectra were collected and analyzed using the Xcalibur MS v 2.0.7 
software package (Thermo Electron Corporation). HPLC separations performed in positive 
mode used a Luna NH2 HILIC column (5µm pore size, 100 Å particle size, 250 x 2.00 mm) 
supplied by Phenomenex. HPLC separations performed in negative mode used a Synergi 
Hydro-RP C18 column (4 µm pore size, 80 Å particle size, 150 x 2.00 mm) supplied by 
Phenomenex. 
 
Cell Extraction Procedure 
832/13 cells were grown to confluence in 15 cm dishes and treated as indicated in the figure 
legends. At the end of the treatment period, cells were washed twice with ice cold phosphate 
buffered saline, scraped and pelleted at 500 x g; the aspirated dry cell pellets were immediately 
flash frozen using liquid N2.  Four individual experiments were performed in duplicate on each of 
3 days. Prior to extraction, the collected cell pellets were weighed, and 30-50 mg of each was 
placed into a microcentrifuge tube at -78 °C. A solution of cold methanol and water (8:2 v/v, 1.5 
mL) kept at -80 °C was then added to the tube to extract the metabolome from the cells. The 
contents were mixed by vortexing and allowed to sit at the extraction temperature for 20 min. 
Particulates were then removed from the samples by centrifugation, and the supernatants were 
transferred to  autosampler vials for further analysis by the LC-MS/MS methods described 
below. 
 
Chromatographic Details 
High performance liquid chromatographic separations of metabolites were performed via a slight 
modification of previously reported methods.91  Due to slight changes, methods are also 
reported below. In total, two HPLC runs are necessary to fully characterize the metabolome for 
each sample since separate detection for positively ionizing and negatively ionizing compounds 
is required. For all samples, 10 µL was injected onto the column via an autosampler. A 
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quaternary pump was used to generate the following gradient for the elution of compounds from 
the stationary phase: 
 
Positive Mode 
The mobile phase flow rate was150 µL/min, and a gradient of two solvents was used for elution. 
Solvent A was a mixture composed of 95% 20 mM ammonium acetate and 20 mM ammonium 
hydroxide in HPLC grade water buffered at pH =  9.4 with 5% HPLC grade acetonitrile. Solvent 
B was pure HPLC grade acetonitrile. These were used to construct the following 40 min 
gradient elution profile: t = 0 min, 15% solvent A, 85% solvent B; t = 15 min, 100% solvent A, 
0% solvent B; t = 28 min, 100% solvent A, 0% solvent B; t = 30, 15% solvent A, 85% solvent B; t 
= 40, 15% solvent A, 85% solvent B. Separations were performed with the column temperature 
set at 10 oC.  
 
Negative Mode 
The mobile phase flow rate was 200 µL/min, and a gradient of two solvents was again used for 
elution. Solvent A consisted of a mixture containing 97% 11 mM  tributylamine and 15 mM 
acetic acid in HPLC grade water and  3% HPLC grade methanol. Solvent B was pure HPLC 
grade methanol. These were used to construct the following 50 min gradient elution profile: t = 0 
min, 100% solvent A, 0% solvent B; t = 5 min, 100% solvent A, 0% solvent B; t = 10 min, 80% 
solvent A, 20% solvent B; t = 15, 80% solvent A, 20% solvent B; t = 30, 35% solvent A, 65% 
solvent B; t = 33, 5% solvent A, 95% solvent B; t = 37, 5% solvent A, 95% solvent B; t = 38, 
100% solvent A, 0% solvent B; t = 50, 100% solvent A, 0% solvent B. Separations were 
performed with the column temperature maintained at 25 oC.  
 
Mass Spectrometric Detection Parameters 
Samples were introduced into the electrospray ionization (ESI) chamber through a 0.1 mm 
internal diameter fused silica capillary after delivery by HPLC as described above. The spray 
voltage for the ESI source was set to 4500 V, if detection occurred in positive ion mode. If 
detection occurred in negative mode, the spray voltage for the ESI source was set to 3000 V. 
Nitrogen was used as the sheath gas (40 psi), and the inlet capillary temperature was 290 °C. 
Argon was used as the collision gas at a pressure of 1.5 mTorr. Samples were analyzed using 
selected reaction monitoring (SRM) with the scan time for each SRM set to 0.05 s and a scan 
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width of 1 m/z. Full selected reaction monitoring (SRM) detection parameters for most 
compounds have been previously reported by Rabinowitz and coworkers.91 
 
Data Handling and Statistical Anaylsis 
The peak for each detected metabolite was manually integrated to determine the peak area 
using the Quan Browser function of Xcalibur. The integration values were then directly entered 
into an Excel spreadsheet where they were normalized to the mass of tissue extracted. Since 
inter-day variability in the ion counts for metabolites was observed due to MS sampling 
variation, the treated samples were compared only to the control samples run on the same day. 
This comparison consisted of averaging the ion counts for the duplicate measurements of a 
metabolite from a treated sample on a given day and then dividing this number by the average 
of the duplicate measurements of the same metabolite from the control sample obtained on the 
same day to generate the fold change for the compound. The fold changes for the metabolite 
from each of the three days were then averaged and clustered and displayed in heat map 
format using the freely available Cluster 3.0 (www.falw.vu/~huik/cluster.htm) and Java 
Treeview92 data analysis packages. The p-value for each metabolite fold change was obtained 
by performing an F-test using the data analysis tool pack in Microsoft Excel. The variance in the 
fold changes for the metabolites in the treatment group was compared to a set of standardized 
fold changes for the metabolites from the control group that was generated by taking the intra-
day ratio of the ion counts from the duplicate measurements of the control. 
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Conclusion 
 
The tools available to a chemist or biologist can greatly impact the scope and quality of research 
conducted. Here, a chemical approach conducted with analytical techniques was applied to the 
study of two biological systems.  Quantitation of both systems, absolute for quorum sensing 
molecules, and relative for the metabolic profiling of rat insulinoma cells, were ultimately 
achieved using LC-MS/MS methods, providing novel results as well as further questions.  
 
The synthesis of stable isotopically labeled AHLs allowed for the quantitation of the naturally 
occurring molecules in four strains of Vibrio fischeri. This synthesis proved to be exceptionally 
valuable for AHL studies in any bacterial system, as it was able to produce any AHL necessary 
with minimal purification.  Additionally, the AI-2 mediated quorum sensing systems of Yersinia 
enterocolitica and Edwardsiella tarda were analyzed. Results from these studies contribute to 
the growing amount of information about quorum sensing systems, and have been useful in 
efforts to better understand these systems.  
 
The application of known LC-MS/MS methods to the study of rat insulinoma cells provided 
visibly distinctive metabolic profiles for two proposed mechanisms of β-cell death. Taken 
together with results from the Collier lab, we were able to conclude that β-cell death in response 
to pro-inflammatory cytokines is unlikely to proceed through an apoptotic mechanism. Further 
studies are currently underway to continue probing these mechanisms metabolically, with the 
ultimate goal of determining the exact cause of pancreatic β-cell death and eventually, T1DM. 
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Table 3: V. fischeri strain ES114 [AHLs] Used in Figure 6A and 7B 
 C6  3OC6  C7 AHL C8 
Time 
(h) 
[AHL] 
Average 
(µM) 
Range 
[AHL] 
Average 
(µM) 
Range 
[AHL] 
Average 
(µM) 
Range 
[AHL] 
Average 
(µM) 
Range 
0 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.007 ± 0.001 
1 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.016 ± 0.001 
2 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.082 ± 0.063 
3 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.023 ± 0.003 
4 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.049 ± 0.002 
5 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.116 ± 0.006 
6 0.011 ± 0.003 0.000 ± 0.000 0.000 ± 0.000 0.251 ± 0.010 
7 0.021 ± 0.003 0.000 ± 0.000 0.000 ± 0.000 0.487 ± 0.021 
8 0.040 ± 0.009 0.000 ± 0.000 0.000 ± 0.000 0.744 ± 0.039 
9 0.073 ± 0.010 0.000 ± 0.000 0.002 ± 0.002 1.175 ± 0.038 
10 0.089 ± 0.002 0.000 ± 0.000 0.000 ± 0.000 1.579 ± 0.068 
11 0.123 ± 0.016 0.000 ± 0.000 0.000 ± 0.000 1.924 ± 0.191 
12 0.147 ± 0.006 0.000 ± 0.000 0.004 ± 0.004 2.134 ± 0.019 
13 0.159 ± 0.001 0.000 ± 0.000 0.002 ± 0.002 2.341 ± 0.178 
14 0.138 ± 0.004 0.000 ± 0.000 0.024 ± 0.024 2.475 ± 0.211 
15 0.132 ± 0.011 0.000 ± 0.000 0.098 ± 0.004 2.394 ± 0.002 
16 0.123 ± 0.001 0.000 ± 0.000 0.113 ± 0.019 2.264 ± 0.081 
17 0.094 ± 0.002 0.000 ± 0.000 0.118 ± 0.013 1.729 ± 0.151 
18 0.136 ± 0.010 0.000 ± 0.000 0.102 ± 0.025 1.764 ± 0.057 
19 0.104 ± 0.005 0.000 ± 0.000 0.082 ± 0.000 1.526 ± 0.120 
20 0.104 ± 0.000 0.000 ± 0.000 0.065 ± 0.002 1.382 ± 0.086 
21 0.081 ± 0.012 0.000 ± 0.000 0.046 ± 0.001 1.166 ± 0.091 
22 0.058 ± 0.002 0.000 ± 0.000 0.046 ± 0.001 1.003 ± 0.120 
23 0.060 ± 0.002 0.000 ± 0.000 0.040 ± 0.008 0.978 ± 0.096 
24 0.052 ± 0.004 0.000 ± 0.000 0.009 ± 0.009 0.640 ± 0.019 
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Table 4: V. fischeri strain MJ-1 [AHLs] Used in Figure 6B and 7A 
 C6  3OC6  C7 AHL C8 
Time 
(h) 
[AHL] 
Average 
(µM) 
Range 
[AHL] 
Average 
(µM) 
Range 
[AHL] 
Average 
(µM) 
Range 
[AHL] 
Average 
(µM) 
Range 
0 0.000 ± 0.000 0.005 ± 0.005 0.000 ± 0.000 0.000 ± 0.000 
1 0.000 ± 0.000 0.012 ± 0.002 0.000 ± 0.000 0.000 ± 0.000 
2 0.000 ± 0.000 0.022 ± 0.005 0.000 ± 0.000 0.000 ± 0.000 
3 0.000 ± 0.000 0.015 ± 0.003 0.000 ± 0.000 0.001 ± 0.001 
4 0.000 ± 0.000 0.018 ± 0.009 0.000 ± 0.000 0.004 ± 0.000 
5 0.000 ± 0.000 0.029 ± 0.002 0.000 ± 0.000 0.017 ± 0.004 
6 0.000 ± 0.000 0.067 ± 0.006 0.000 ± 0.000 0.041 ± 0.004 
7 0.000 ± 0.000 0.091 ± 0.011 0.000 ± 0.000 0.073 ± 0.010 
8 0.011 ± 0.003 0.125 ± 0.046 0.000 ± 0.000 0.121 ± 0.003 
9 0.015 ± 0.007 0.158 ± 0.035 0.000 ± 0.000 0.139 ± 0.006 
10 0.026 ± 0.003 0.253 ± 0.058 0.000 ± 0.000 0.193 ± 0.031 
11 0.037 ± 0.001 0.184 ± 0.063 0.000 ± 0.000 0.186 ± 0.000 
12 0.028 ± 0.004 0.287 ± 0.041 0.000 ± 0.000 0.199 ± 0.008 
13 0.047 ± 0.007 0.209 ± 0.014 0.000 ± 0.000 0.213 ± 0.002 
14 0.027 ± 0.002 0.223 ± 0.013 0.000 ± 0.000 0.250 ± 0.010 
15 0.038 ± 0.010 0.150 ± 0.028 0.000 ± 0.000 0.230 ± 0.017 
16 0.026 ± 0.003 0.160 ± 0.027 0.021 ± 0.000 0.209 ± 0.011 
17 0.024 ± 0.002 0.115 ± 0.024 0.034 ± 0.005 0.161 ± 0.010 
18 0.032 ± 0.001 0.095 ± 0.008 0.034 ± 0.003 0.147 ± 0.020 
19 0.019 ± 0.001 0.073 ± 0.013 0.026 ± 0.001 0.159 ± 0.007 
20 0.022 ± 0.010 0.044 ± 0.010 0.022 ± 0.005 0.118 ± 0.014 
21 0.019 ± 0.001 0.040 ± 0.005 0.015 ± 0.002 0.098 ± 0.003 
22 0.016 ± 0.005 0.028 ± 0.003 0.026 ± 0.004 0.071 ± 0.006 
23 0.004 ± 0.004 0.013 ± 0.000 0.005 ± 0.005 0.073 ± 0.012 
24 0.000 ± 0.000 0.009 ± 0.009 0.000 ± 0.000 0.058 ± 0.009 
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Table 5: V. fischeri strain CL21 [AHLs] Used in Figure 6C  
 C6  3OC6  C7 AHL C8 
Time 
(h) 
[AHL] 
Average 
(µM) 
Range 
[AHL] 
Average 
(µM) 
Range 
[AHL] 
Average 
(µM) 
Range 
[AHL] 
Average 
(µM) 
Range 
0 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 
1 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 
2 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 
3 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 
4 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 
5 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 
6 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 
7 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 
8 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 
9 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 
10 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 
11 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 
12 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 
13 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 
14 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 
15 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 
16 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 
17 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 
18 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 
19 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 
20 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 
21 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 
22 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 
23 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 
24 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 
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Table 6: V. fischeri strain VCW2G7 [AHLs] Used in Figure 6D 
 C6  3OC6  C7 AHL C8 
Time 
(h) 
[AHL] 
Average 
(µM) 
Range 
[AHL] 
Average 
(µM) 
Range 
[AHL] 
Average 
(µM) 
Range 
[AHL] 
Average 
(µM) 
Range 
0 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 
1 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.003 ± 0.001 
2 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.004 ± 0.001 
3 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.010 ± 0.001 
4 0.000 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.054 ± 0.004 
5 0.008 ± 0.008 0.000 ± 0.000 0.000 ± 0.000 0.232 ± 0.009 
6 0.017 ± 0.004 0.000 ± 0.000 0.000 ± 0.000 0.456 ± 0.006 
7 0.033 ± 0.016 0.000 ± 0.000 0.000 ± 0.000 0.807 ± 0.060 
8 0.038 ± 0.003 0.000 ± 0.000 0.000 ± 0.000 1.116 ± 0.039 
9 0.062 ± 0.001 0.000 ± 0.000 0.000 ± 0.000 1.627 ± 0.160 
10 0.088 ± 0.006 0.000 ± 0.000 0.000 ± 0.000 1.866 ± 0.146 
11 0.130 ± 0.020 0.000 ± 0.000 0.000 ± 0.000 2.073 ± 0.241 
12 0.112 ± 0.003 0.000 ± 0.000 0.000 ± 0.000 2.251 ± 0.097 
13 0.117 ± 0.003 0.000 ± 0.000 0.000 ± 0.000 2.100 ± 0.141 
14 0.125 ± 0.018 0.000 ± 0.000 0.001 ± 0.001 2.051 ± 0.187 
15 0.123 ± 0.004 0.000 ± 0.000 0.005 ± 0.005 2.078 ± 0.141 
16 0.109 ± 0.000 0.000 ± 0.000 0.083 ± 0.014 1.834 ± 0.080 
17 0.116 ± 0.008 0.000 ± 0.000 0.128 ± 0.009 1.540 ± 0.007 
18 0.092 ± 0.001 0.000 ± 0.000 0.103 ± 0.015 1.474 ± 0.074 
19 0.096 ± 0.013 0.000 ± 0.000 0.101 ± 0.001 1.276 ± 0.087 
20 0.071 ± 0.003 0.000 ± 0.000 0.088 ± 0.012 1.053 ± 0.091 
21 0.063 ± 0.004 0.000 ± 0.000 0.103 ± 0.018 0.922 ± 0.045 
22 0.049 ± 0.007 0.000 ± 0.000 0.049 ± 0.004 0.685 ± 0.091 
23 0.039 ± 0.008 0.000 ± 0.000 0.036 ± 0.009 0.615 ± 0.109 
24 0.020 ± 0.008 0.000 ± 0.000 0.032 ± 0.005 0.489 ± 0.084 
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Table 7: V. fischeri Cell Densities Used in Figure 6E 
 ES114 MJ-1 CL21 VCW2G7 
Time 
(h) 
Cell 
Density 
Average 
(OD600) 
Range 
Cell 
Density 
Average 
(OD600) 
Range 
Cell 
Density 
Average 
(OD600) 
Range 
Cell 
Density 
Average 
(OD600) 
Range 
0 0.00 ± 0.00 0.00 ± 0.00 0.04 ± 0.00 0.04 ± 0.00 
1 0.08 ± 0.00 0.05 ± 0.00 0.08 ± 0.00 0.10 ± 0.00 
2 0.31 ± 0.00 0.30 ± 0.00 0.30 ± 0.00 0.36 ± 0.01 
3 0.54 ± 0.00 0.73 ± 0.01 0.64 ± 0.00 0.80 ± 0.02 
4 0.68 ± 0.00 1.10 ± 0.00 0.98 ± 0.00 1.22 ± 0.01 
5 1.03 ± 0.01 1.45 ± 0.00 1.43 ± 0.01 1.88 ± 0.05 
6 1.58 ± 0.01 1.83 ± 0.11 1.80 ± 0.02 2.42 ± 0.05 
7 2.17 ± 0.15 2.30 ± 0.05 2.27 ± 0.04 2.88 ± 0.07 
8 2.62 ± 0.06 2.72 ± 0.13 2.63 ± 0.07 3.27 ± 0.08 
9 3.09 ± 0.09 3.16 ± 0.13 3.30 ± 0.10 3.68 ± 0.01 
10 3.40 ± 0.10 3.51 ± 0.09 3.41 ± 0.01 3.94 ± 0.07 
11 3.86 ± 0.04 3.77 ± 0.16 3.86 ± 0.20 4.28 ± 0.02 
12 4.08 ± 0.06 4.19 ± 0.09 4.16 ± 0.14 4.74 ± 0.02 
13 4.23 ± 0.02 4.31 ± 0.06 4.24 ± 0.13 4.86 ± 0.03 
14 4.41 ± 0.03 4.52 ± 0.07 4.61 ± 0.00 5.15 ± 0.13 
15 4.62 ± 0.00 4.82 ± 0.16 4.76 ± 0.06 5.52 ± 0.02 
16 4.52 ± 0.02 5.00 ± 0.05 5.16 ± 0.14 5.86 ± 0.05 
17 4.60 ± 0.07 5.20 ± 0.01 5.32 ± 0.15 5.93 ± 0.03 
18 4.67 ± 0.02 5.24 ± 0.03 5.50 ± 0.09 6.18 ± 0.12 
19 4.66 ± 0.00 5.10 ± 0.04 5.92 ± 0.04 6.37 ± 0.07 
20 4.63 ± 0.06 5.13 ± 0.03 5.60 ± 0.04 5.99 ± 0.07 
21 4.65 ± 0.04 5.28 ± 0.00 5.52 ± 0.06 5.96 ± 0.08 
22 4.72 ± 0.14 5.36 ± 0.06 5.69 ± 0.07 5.89 ± 0.02 
23 4.65 ± 0.02 5.21 ± 0.02 5.63 ± 0.11 5.94 ± 0.08 
24 4.65 ± 0.08 5.25 ± 0.01 5.91 ± 0.07 5.84 ± 0.04 
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Table 8: V. fischeri strains MJ-1 and ES114 [DPD] Used in Figure 7 
 MJ-1 ES114 
Time 
(h) 
[DPD] 
(µM) 
Range 
[DPD] 
(µM) 
Range 
0 0.25 ± 0.04 0.34 ± 0.01 
1 0.30 ± 0.02 0.32 ± 0.02 
2 0.51 ± 0.04 0.53 ± 0.03 
3 1.33 ± 0.00 1.33 ± 0.00 
4 1.88 ± 0.00 1.88 ± 0.00 
5 1.52 ± 0.00 1.52 ± 0.00 
6 0.70 ± 0.05 1.28 ± 0.00 
7 0.71 ± 0.00 1.21 ± 0.00 
8 0.69 ± 0.14 1.03 ± 0.08 
9 0.59 ± 0.10 0.78 ± 0.05 
10 0.66 ± 0.01 0.64 ± 0.00 
11 0.72 ± 0.00 0.67 ± 0.09 
12 0.53 ± 0.09 0.45 ± 0.08 
13 0.35 ± 0.09 0.44 ± 0.10 
14 0.32 ± 0.00 0.39 ± 0.10 
15 0.33 ± 0.08 0.33 ± 0.01 
16 0.47 ± 0.05 0.42 ± 0.02 
17 0.25 ± 0.04 0.36 ± 0.01 
18 0.24 ± 0.02 0.26 ± 0.02 
19 0.30 ± 0.08 0.26 ± 0.09 
20 0.32 ± 0.07 0.24 ± 0.06 
21 0.26 ± 0.01 0.32 ± 0.13 
22 0.25 ± 0.03 0.30 ± 0.05 
23 0.25 ± 0.06 0.22 ± 0.13 
24 0.17 ± 0.04 0.18 ± 0.00 
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Table 9: E. tarda No Added Glucose and 0.14% Glucose Cell Density and 
[DPD] Figure 8 
 No Added Glucose 0.14% Glucose 
Time 
(h) 
Cell Density 
(OD600) 
[DPD] 
(µM) 
Cell Density 
(OD600) 
[DPD] 
(µM) 
0 0.01 0.30 0.01 0.32 
1 0.04 0.49 0.04 0.39 
2 0.08 0.58 0.09 0.59 
3 0.23 1.06 0.25 1.05 
4 0.50 2.24 0.56 2.44 
5 0.74 3.38 1.25 6.10 
6 1.04 6.00 2.30 10.58 
7 1.49 9.15 3.04 23.15 
8 1.60 11.82 3.50 40.82 
9 1.90 15.37 3.62 56.01 
10 2.20 20.15 3.69 68.49 
11 2.56 23.82 3.68 76.08 
12 2.94 31.62 3.91 87.48 
13 2.91 27.92 3.77 89.63 
14 3.12 9.82 3.99 99.66 
15 3.30 0.06 4.03 98.99 
16 3.59 0.05 4.00 107.71 
17 3.77 0.06 4.42 112.09 
18 4.12 0.05 4.66 103.73 
19 4.14 0.05 4.84 89.27 
20 4.42 0.53 5.05 40.18 
21 4.45 0.83 5.51 0.96 
22 4.50 0.73 5.60 0.69 
23 4.56 0.78 5.98 0.73 
24 4.52 0.71 6.17 0.43 
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Table 10: Y. enterocolitica No Added Glucose Cell Density and [DPD]/OD 
Used in Figure 9 
Time 
(h) 
Cell Density 
Average 
(OD600) 
Range 
[DPD]/OD 
Average 
(M/OD600) 
Range 
1 0.03 ± 0.00 25.13 ± 0.66 
2 0.07 ± 0.00 13.78 ± 0.22 
3 0.14 ± 0.00 7.44 ± 0.21 
4 0.31 ± 0.00 4.72 ± 0.10 
5 0.52 ± 0.02 4.41 ± 0.11 
6 0.95 ± 0.01 4.82 ± 0.02 
7 1.68 ± 0.03 6.06 ± 0.09 
8 2.25 ± 0.06 11.43 ± 0.31 
9 2.40 ± 0.15 22.45 ± 0.93 
10 2.94 ± 0.05 26.75 ± 0.54 
11 3.26 ± 0.13 20.44 ± 1.22 
12 3.46 ± 0.14 8.53 ± 0.18 
13 3.69 ± 0.10 0.17 ± 0.14 
14 3.79 ± 0.11 0.13 ± 0.11 
15 4.05 ± 0.05 0.09 ± 0.08 
16 4.05 ± 0.05 0.08 ± 0.07 
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Table 11: Y. enterocolitica 0.08% Glucose Cell Density and [DPD]/OD 
Used in Figure 9 
Time 
(h) 
Cell Density 
Average 
(OD600) 
Range 
[DPD]/OD 
Average 
(M/OD600) 
Range 
1 0.03 ± 0.00 26.48 ± 0.05 
2 0.07 ± 0.00 13.75 ± 0.32 
3 0.14 ± 0.00 7.49 ± 0.17 
4 0.31 ± 0.01 4.74 ± 0.07 
5 0.51 ± 0.01 4.34 ± 0.17 
6 0.90 ± 0.02 4.80 ± 0.05 
7 1.53 ± 0.05 6.22 ± 0.03 
8 2.00 ± 0.04 11.68 ± 0.39 
9 2.19 ± 0.06 24.32 ± 0.02 
10 2.63 ± 0.15 34.15 ± 0.47 
11 2.99 ± 0.08 36.54 ± 0.39 
12 3.50 ± 0.14 24.61 ± 1.38 
13 3.73 ± 0.01 8.49 ± 0.19 
14 4.02 ± 0.02 0.34 ± 0.01 
15 4.22 ± 0.02 0.24 ± 0.00 
16 4.22 ± 0.02 0.22 ± 0.04 
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Table 12: Y. enterocolitica 0.14% Glucose Cell Density and [DPD]/OD 
Used in Figure 9 
Time 
(h) 
Cell Density 
Average 
(OD600) 
Range 
[DPD]/OD 
Average 
(M/OD600) 
Range 
1 0.03 ± 0.00 45.97 ± 6.89 
2 0.05 ± 0.00 22.07 ± 2.99 
3 0.11 ± 0.00 10.97 ± 0.35 
4 0.25 ± 0.01 5.80 ± 0.10 
5 0.46 ± 0.01 4.71 ± 0.05 
6 0.86 ± 0.01 4.80 ± 0.11 
7 1.71 ± 0.00 5.48 ± 0.28 
8 2.19 ± 0.04 10.10 ± 0.73 
9 2.69 ± 0.03 18.53 ± 1.00 
10 3.13 ± 0.03 27.53 ± 1.21 
11 3.52 ± 0.04 31.50 ± 0.39 
12 3.88 ± 0.01 20.17 ± 0.85 
13 4.20 ± 0.07 2.76 ± 1.05 
14 4.37 ± 0.03 0.51 ± 0.04 
15 4.63 ± 0.05 0.31 ± 0.03 
16 4.89 ± 0.06 0.32 ± 0.05 
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Table 13: Y. enterocolitica 0.20% Glucose Cell Density and [DPD]/OD 
Used in Figure 9 
Time 
(h) 
Cell Density 
Average 
(OD600) 
Range 
[DPD]/OD 
Average 
(M/OD600) 
Range 
1 0.03 ± 0.00 38.42 ± 1.50 
2 0.05 ± 0.00 19.17 ± 0.49 
3 0.12 ± 0.00 10.17 ± 0.16 
4 0.25 ± 0.00 5.86 ± 0.11 
5 0.47 ± 0.00 4.83 ± 0.03 
6 0.87 ± 0.01 4.96 ± 0.01 
7 1.73 ± 0.03 5.72 ± 0.02 
8 2.20 ± 0.00 10.18 ± 0.14 
9 2.67 ± 0.02 20.07 ± 0.44 
10 3.11 ± 0.02 27.86 ± 0.21 
11 3.60 ± 0.05 31.98 ± 1.56 
12 3.96 ± 0.05 24.58 ± 0.74 
13 4.30 ± 0.05 5.89 ± 0.66 
14 4.47 ± 0.02 0.45 ± 0.00 
15 4.72 ± 0.04 0.34 ± 0.00 
16 5.03 ± 0.02 0.24 ± 0.01 
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Table 14: Y. enterocolitica No Added Glucose [DPD] and % Glucose Used 
in Figure 10A 
Time 
(h) 
[DPD] 
Average 
(M) 
Range 
% Glucose  
Average 
(% (w/v)) 
Range 
0 0.78 ± 0.02 0.15 ± 0.01 
1 0.84 ± 0.02 0.14 ± 0.01 
2 0.91 ± 0.01 0.12 ± 0.00 
3 1.05 ± 0.00 0.11 ± 0.00 
4 1.47 ± 0.01 0.10 ± 0.00 
5 2.31 ± 0.01 0.08 ± 0.00 
6 4.56 ± 0.04 0.08 ± 0.00 
7 10.18 ± 0.07 0.07 ± 0.01 
8 25.71 ± 0.02 0.02 ± 0.00 
9 53.69 ± 1.19 -0.01 ± 0.00 
10 78.62 ± 0.24 -0.01 ± 0.00 
11 66.37 ± 1.31 -0.01 ± 0.00 
12 29.48 ± 0.59 -0.01 ± 0.00 
13 0.63 ± 0.51 -0.01 ± 0.00 
14 0.47 ± 0.39 -0.01 ± 0.00 
15 0.37 ± 0.31 0.00 ± 0.00 
16 0.33 ± 0.27 -0.01 ± 0.00 
A500 = 6.808  [       ] + 0.4399; R² = 0.9938 
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Table 15: Y. enterocolitica 0.08% Glucose [DPD] and % Glucose Used in 
Figure 10B 
Time 
(h) 
[DPD] 
Average 
(M) 
Range 
% Glucose  
Average 
(% (w/v)) 
Range 
0 0.78 ± 0.01 0.12 ± 0.01 
1 0.81 ± 0.01 0.10 ± 0.01 
2 0.91 ± 0.01 0.10 ± 0.01 
3 1.02 ± 0.04 0.10 ± 0.02 
4 1.45 ± 0.00 0.10 ± 0.01 
5 2.20 ± 0.13 0.10 ± 0.02 
6 4.32 ± 0.13 0.10 ± 0.01 
7 9.48 ± 0.24 0.11 ± 0.01 
8 23.31 ± 1.24 0.08 ± 0.02 
9 53.13 ± 1.29 0.04 ± 0.02 
10 89.75 ± 3.89 0.00 ± 0.01 
11 109.14 ± 1.66 0.01 ± 0.02 
12 85.84 ± 1.51 0.00 ± 0.02 
13 31.63 ± 0.68 0.00 ± 0.01 
14 1.37 ± 0.03 0.00 ± 0.01 
15 0.99 ± 0.00 0.00 ± 0.01 
16 0.93 ± 0.15 0.00 ± 0.01 
A500 = 5.869  [       ] + 0.2882; R² = 0.9849 
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Table 16: Y. enterocolitica 0.14% Glucose [DPD] and % Glucose Used in 
Figure 10C 
Time 
(h) 
[DPD] 
Average 
(M) 
Range 
% Glucose  
Average 
(% (w/v)) 
Range 
0 0.77 ± 0.02 0.12 ± 0.02 
1 1.15 ± 0.17 0.16 ± 0.01 
2 1.12 ± 0.11 0.15 ± 0.03 
3 1.24 ± 0.07 0.17 ± 0.04 
4 1.46 ± 0.03 0.15 ± 0.03 
5 2.15 ± 0.02 0.15 ± 0.01 
6 4.11 ± 0.15 0.16 ± 0.01 
7 9.35 ± 0.48 0.14 ± 0.01 
8 22.04 ± 1.25 0.14 ± 0.02 
9 49.77 ± 2.18 0.06 ± 0.01 
10 86.00 ± 2.95 0.00 ± 0.01 
11 110.93 ± 0.04 -0.01 ± 0.02 
12 78.33 ± 3.43 -0.01 ± 0.02 
13 11.65 ± 4.58 0.00 ± 0.02 
14 2.24 ± 0.21 -0.01 ± 0.02 
15 1.45 ± 0.15 -0.01 ± 0.02 
16 1.58 ± 0.28 -0.01 ± 0.02 
A500 = 5.869  [       ] + 0.2882; R² = 0.9849 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
93 
 
Table 17: Y. enterocolitica 0.20% Glucose [DPD] and % Glucose Used in 
Figure 10D 
Time 
(h) 
[DPD] 
Average 
(M) 
Range 
% Glucose  
Average 
(% (w/v)) 
Range 
0 0.86 ± 0.01 0.14 ± 0.04 
1 1.00 ± 0.00 0.17 ± 0.01 
2 1.03 ± 0.01 0.17 ± 0.02 
3 1.18 ± 0.04 0.18 ± 0.01 
4 1.49 ± 0.03 0.19 ± 0.01 
5 2.26 ± 0.01 0.20 ± 0.00 
6 4.29 ± 0.06 0.22 ± 0.00 
7 9.87 ± 0.14 0.19 ± 0.02 
8 22.37 ± 0.29 0.17 ± 0.03 
9 53.50 ± 1.57 0.09 ± 0.02 
10 86.51 ± 0.04 0.04 ± 0.02 
11 115.12 ± 4.10 -0.01 ± 0.02 
12 97.29 ± 1.72 -0.01 ± 0.02 
13 25.27 ± 2.56 0.00 ± 0.02 
14 2.00 ± 0.03 -0.01 ± 0.01 
15 1.58 ± 0.00 0.00 ± 0.02 
16 1.19 ± 0.02 0.00 ± 0.02 
A500 = 5.869  [       ] + 0.2882; R² = 0.9849 
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Table 18: Y. enterocolitica No Added Glucose Cell Density and [DPD]/OD 
Used in Figure 11 
Time 
(h) 
Cell Density 
Average 
(OD600) 
Range 
[DPD]/OD 
Average 
(M/OD600) 
Range 
1 0.02 ± 0.00 18.35 ± 0.87 
2 0.04 ± 0.00 10.41 ± 0.41 
3 0.11 ± 0.00 5.48 ± 0.05 
4 0.24 ± 0.02 4.16 ± 0.38 
5 0.52 ± 0.01 4.14 ± 0.13 
6 0.82 ± 0.05 5.84 ± 0.22 
7 1.50 ± 0.04 6.00 ± 0.35 
8 1.73 ± 0.06 6.39 ± 0.38 
9 1.92 ± 0.09 4.95 ± 0.16 
10 2.25 ± 0.11 1.62 ± 0.20 
11 2.54 ± 0.09 0.27 ± 0.00 
12 2.84 ± 0.09 0.20 ± 0.00 
13 3.11 ± 0.10 0.18 ± 0.01 
14 3.48 ± 0.07 0.17 ± 0.01 
15 3.72 ± 0.16 0.14 ± 0.01 
16 4.03 ± 0.10 0.12 ± 0.00 
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Table 19: Y. enterocolitica 0.08% Glucose Cell Density and [DPD]/OD 
Used in Figure 11 
Time 
(h) 
Cell Density 
Average 
(OD600) 
Range 
[DPD]/OD 
Average 
(M/OD600) 
Range 
1 0.02 ± 0.00 16.84 ± 0.19 
2 0.05 ± 0.00 9.90 ± 0.52 
3 0.12 ± 0.00 5.38 ± 0.01 
4 0.27 ± 0.00 3.79 ± 0.04 
5 0.59 ± 0.01 4.62 ± 0.10 
6 0.88 ± 0.01 8.76 ± 0.05 
7 1.44 ± 0.10 13.38 ± 0.62 
8 1.70 ± 0.05 19.39 ± 0.36 
9 2.01 ± 0.08 25.11 ± 2.20 
10 2.38 ± 0.12 24.64 ± 1.41 
11 2.81 ± 0.15 15.52 ± 1.57 
12 2.97 ± 0.07 3.47 ± 1.77 
13 3.19 ± 0.05 0.23 ± 0.01 
14 3.43 ± 0.04 0.19 ± 0.01 
15 3.73 ± 0.06 0.14 ± 0.01 
16 4.06 ± 0.03 0.12 ± 0.00 
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Table 20: Y. enterocolitica 0.14% Glucose Cell Density and [DPD]/OD 
Used in Figure 11 
Time 
(h) 
Cell Density 
Average 
(OD600) 
Range 
[DPD]/OD 
Average 
(M/OD600) 
Range 
1 0.02 ± 0.00 23.59 ± 0.95 
2 0.05 ± 0.00 11.45 ± 0.04 
3 0.13 ± 0.00 5.11 ± 0.15 
4 0.32 ± 0.01 3.86 ± 0.05 
5 0.66 ± 0.02 4.83 ± 0.05 
6 1.08 ± 0.01 7.51 ± 0.14 
7 1.70 ± 0.00 11.26 ± 0.25 
8 1.95 ± 0.08 18.71 ± 0.68 
9 2.32 ± 0.03 25.04 ± 1.06 
10 2.62 ± 0.04 28.56 ± 0.07 
11 3.02 ± 0.05 25.34 ± 0.96 
12 3.29 ± 0.04 16.24 ± 0.57 
13 3.38 ± 0.01 6.97 ± 0.43 
14 3.42 ± 0.01 0.27 ± 0.01 
15 3.64 ± 0.00 0.21 ± 0.02 
16 3.92 ± 0.06 0.18 ± 0.01 
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Table 21: Y. enterocolitica 0.20% Glucose Cell Density and [DPD]/OD 
Used in Figure 11 
Time 
(h) 
Cell Density 
Average 
(OD600) 
Range 
[DPD]/OD 
Average 
(M/OD600) 
Range 
1 0.02 ± 0.00 24.32 ± 0.39 
2 0.05 ± 0.00 10.33 ± 0.04 
3 0.13 ± 0.00 5.51 ± 0.08 
4 0.31 ± 0.01 3.86 ± 0.16 
5 0.67 ± 0.00 4.60 ± 0.04 
6 1.10 ± 0.02 7.79 ± 0.33 
7 1.68 ± 0.00 11.81 ± 0.32 
8 1.98 ± 0.02 18.58 ± 0.58 
9 2.38 ± 0.02 26.89 ± 0.08 
10 2.62 ± 0.07 32.92 ± 0.37 
11 3.01 ± 0.08 32.36 ± 1.12 
12 3.31 ± 0.06 26.24 ± 1.07 
13 3.49 ± 0.13 18.55 ± 2.00 
14 3.55 ± 0.11 7.56 ± 1.65 
15 3.47 ± 0.41 0.29 ± 0.01 
16 4.03 ± 0.19 0.21 ± 0.00 
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Table 22: Y. enterocolitica 0.30% Glucose Cell Density and [DPD]/OD 
Used in Figure 11 
Time 
(h) 
Cell Density 
Average 
(OD600) 
Range 
[DPD]/OD 
Average 
(M/OD600) 
Range 
1 0.03 ± 0.00 19.61 ± 1.59 
2 0.07 ± 0.01 9.25 ± 1.26 
3 0.18 ± 0.00 4.99 ± 0.22 
4 0.48 ± 0.00 4.82 ± 0.86 
5 0.99 ± 0.00 5.16 ± 0.07 
6 1.79 ± 0.03 9.78 ± 0.34 
7 2.27 ± 0.17 17.49 ± 0.54 
8 2.35 ± 0.06 26.68 ± 0.34 
9 2.48 ± 0.05 30.74 ± 0.48 
10 2.89 ± 0.11 31.52 ± 0.04 
11 3.10 ± 0.03 33.89 ± 0.43 
12 3.21 ± 0.06 33.48 ± 1.25 
13 3.48 ± 0.04 29.77 ± 0.17 
14 3.69 ± 0.06 25.94 ± 0.80 
15 3.96 ± 0.07 24.58 ± 1.61 
16 4.30 ± 0.12 18.27 ± 1.33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
99 
 
Table 23: Y. enterocolitica 0.50% Glucose Cell Density and [DPD]/OD 
Used in Figure 11 
Time 
(h) 
Cell Density 
Average 
(OD600) 
Range 
[DPD]/OD 
Average 
(M/OD600) 
Range 
1 0.02 ± 0.00 21.41 ± 0.17 
2 0.07 ± 0.01 8.84 ± 0.87 
3 0.18 ± 0.00 4.89 ± 0.12 
4 0.49 ± 0.00 3.96 ± 0.01 
5 0.98 ± 0.00 5.58 ± 0.06 
6 1.83 ± 0.03 10.33 ± 0.32 
7 2.33 ± 0.01 17.64 ± 0.71 
8 2.35 ± 0.02 26.04 ± 0.22 
9 2.59 ± 0.02 29.33 ± 0.45 
10 2.83 ± 0.05 33.39 ± 0.76 
11 3.09 ± 0.04 32.82 ± 2.39 
12 3.28 ± 0.02 34.26 ± 0.10 
13 3.59 ± 0.02 30.18 ± 0.13 
14 3.72 ± 0.05 33.29 ± 0.91 
15 3.62 ± 0.22 34.40 ± 3.15 
16 4.00 ± 0.02 27.45 ± 1.60 
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Table 24: Y. enterocolitica No Added Glucose [DPD] and % Glucose Used 
in Figure 12A 
Time 
(h) 
[DPD] 
Average 
(M) 
Range 
% Glucose  
Average 
(% (w/v)) 
Range 
0 0.39 ± 0.00 -0.01 ± 0.00 
1 0.41 ± 0.01 -0.01 ± 0.00 
2 0.45 ± 0.00 -0.01 ± 0.00 
3 0.59 ± 0.02 0.00 ± 0.00 
4 0.98 ± 0.01 -0.01 ± 0.00 
5 2.15 ± 0.10 -0.01 ± 0.00 
6 4.78 ± 0.10 -0.01 ± 0.00 
7 9.01 ± 0.30 -0.01 ± 0.01 
8 11.03 ± 0.27 -0.03 ± 0.01 
9 9.50 ± 0.14 -0.02 ± 0.00 
10 3.62 ± 0.28 -0.01 ± 0.00 
11 0.68 ± 0.03 -0.01 ± 0.00 
12 0.57 ± 0.01 -0.01 ± 0.00 
13 0.57 ± 0.01 -0.01 ± 0.00 
14 0.58 ± 0.03 -0.01 ± 0.00 
15 0.51 ± 0.01 -0.01 ± 0.01 
16 0.49 ± 0.01 -0.02 ± 0.00 
A500 = 4.197 [       ] + 0.4597; R² = 0.9966 
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Table 25: Y. enterocolitica 0.08% Glucose [DPD] and % Glucose Used in 
Figure 12B 
Time 
(h) 
[DPD] 
Average 
(M) 
Range 
% Glucose  
Average 
(% (w/v)) 
Range 
0 0.34 ± 0.00 0.12 ± 0.01 
1 0.40 ± 0.00 0.11 ± 0.03 
2 0.47 ± 0.01 0.12 ± 0.03 
3 0.62 ± 0.01 0.13 ± 0.03 
4 1.04 ± 0.02 0.15 ± 0.01 
5 2.74 ± 0.01 0.11 ± 0.01 
6 7.72 ± 0.11 0.07 ± 0.00 
7 19.14 ± 0.38 -0.01 ± 0.00 
8 32.94 ± 0.45 -0.02 ± 0.00 
9 50.34 ± 2.36 -0.02 ± 0.00 
10 58.54 ± 0.46 -0.01 ± 0.01 
11 43.39 ± 2.17 -0.01 ± 0.00 
12 10.17 ± 5.03 -0.01 ± 0.00 
13 0.73 ± 0.03 -0.01 ± 0.00 
14 0.63 ± 0.02 -0.01 ± 0.00 
15 0.52 ± 0.01 -0.01 ± 0.01 
16 0.48 ± 0.02 -0.03 ± 0.00 
A500 = 4.197 [       ] + 0.4597; R² = 0.9966 
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Table 26: Y. enterocolitica 0.14% Glucose [DPD] and % Glucose Used in 
Figure 12C 
Time 
(h) 
[DPD] 
Average 
(M) 
Range 
% Glucose  
Average 
(%(w/v)) 
Range 
0 0.31 ± 0.00 0.17 ± 0.01 
1 0.38 ± 0.02 0.14 ± 0.01 
2 0.52 ± 0.02 0.16 ± 0.03 
3 0.66 ± 0.03 0.19 ± 0.02 
4 1.24 ± 0.04 0.18 ± 0.02 
5 3.18 ± 0.08 0.17 ± 0.01 
6 8.10 ± 0.19 0.14 ± 0.02 
7 19.08 ± 0.42 0.08 ± 0.01 
8 36.33 ± 0.07 0.01 ± 0.01 
9 58.01 ± 1.64 -0.02 ± 0.00 
10 74.70 ± 1.47 -0.01 ± 0.01 
11 76.43 ± 1.68 -0.01 ± 0.00 
12 53.46 ± 1.27 0.00 ± 0.00 
13 23.57 ± 1.49 -0.01 ± 0.00 
14 0.92 ± 0.02 0.00 ± 0.00 
15 0.78 ± 0.07 -0.01 ± 0.00 
16 0.69 ± 0.04 -0.02 ± 0.00 
A500 = 4.197 [       ] + 0.4597; R² = 0.9966 
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Table 27: Y. enterocolitica 0.20% Glucose [DPD] and % Glucose Used in 
Figure 12D 
Time 
(h) 
[DPD] 
Average 
(M) 
Range 
% Glucose  
Average 
(% (w/v)) 
Range 
0 0.31 ± 0.01 0.15 ± 0.02 
1 0.39 ± 0.01 0.16 ± 0.00 
2 0.48 ± 0.01 0.16 ± 0.00 
3 0.71 ± 0.01 0.15 ± 0.03 
4 1.20 ± 0.01 0.15 ± 0.00 
5 3.07 ± 0.03 0.16 ± 0.01 
6 8.57 ± 0.18 0.12 ± 0.01 
7 19.81 ± 0.50 0.12 ± 0.01 
8 36.77 ± 0.69 0.07 ± 0.01 
9 64.01 ± 0.87 0.00 ± 0.01 
10 86.12 ± 3.27 -0.01 ± 0.00 
11 97.31 ± 0.77 -0.01 ± 0.00 
12 86.73 ± 2.05 -0.01 ± 0.01 
13 64.49 ± 4.67 -0.01 ± 0.01 
14 26.68 ± 5.05 -0.01 ± 0.00 
15 1.01 ± 0.08 -0.01 ± 0.00 
16 0.83 ± 0.05 -0.02 ± 0.00 
A500 = 6.034  [       ] + 0.4786; R² = 0.9997 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
104 
 
Table 28: Y. enterocolitica 0.30% Glucose [DPD] and % Glucose Used in 
Figure 12E 
Time 
(h) 
[DPD] 
Average 
(M) 
Range 
% Glucose  
Average 
(% (w/v)) 
Range 
0 0.47 ± 0.02 0.19 ± 0.01 
1 0.49 ± 0.02 0.16 ± 0.03 
2 0.64 ± 0.00 0.16 ± 0.01 
3 0.88 ± 0.03 0.19 ± 0.02 
4 2.29 ± 0.41 0.17 ± 0.02 
5 5.13 ± 0.06 0.17 ± 0.03 
6 17.52 ± 0.34 0.16 ± 0.01 
7 39.60 ± 1.65 0.14 ± 0.01 
8 62.79 ± 2.33 0.10 ± 0.00 
9 76.33 ± 2.82 0.06 ± 0.00 
10 91.00 ± 3.42 0.03 ± 0.01 
11 105.07 ± 2.36 -0.02 ± 0.00 
12 107.39 ± 2.17 -0.02 ± 0.00 
13 103.53 ± 1.72 -0.01 ± 0.00 
14 95.55 ± 1.25 -0.02 ± 0.00 
15 97.24 ± 4.77 -0.02 ± 0.00 
16 78.45 ± 3.48 -0.02 ± 0.00 
A500 = 6.034  [       ] + 0.4786; R² = 0.9997 
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Table 29: Y. enterocolitica 0.50% Glucose [DPD] and % Glucose Used in 
Figure 12F 
Time 
(h) 
[DPD] 
Average 
(M) 
Range 
% Glucose  
Average 
(% (w/v)) 
Range 
0 0.48 ± 0.01 0.21 ± 0.01 
1 0.51 ± 0.02 0.22 ± 0.00 
2 0.61 ± 0.01 0.22 ± 0.01 
3 0.86 ± 0.01 0.20 ± 0.01 
4 1.92 ± 0.00 0.20 ± 0.01 
5 5.50 ± 0.04 0.20 ± 0.00 
6 18.85 ± 0.28 0.20 ± 0.00 
7 41.14 ± 1.80 0.20 ± 0.02 
8 61.26 ± 0.06 0.17 ± 0.00 
9 75.80 ± 0.57 0.18 ± 0.01 
10 94.46 ± 0.48 0.17 ± 0.01 
11 101.32 ± 6.23 0.15 ± 0.01 
12 112.46 ± 0.43 0.11 ± 0.01 
13 108.18 ± 1.09 0.03 ± 0.01 
14 123.63 ± 1.72 -0.01 ± 0.00 
15 123.86 ± 3.73 -0.01 ± 0.00 
16 109.69 ± 5.93 -0.02 ± 0.00 
A500 = 6.034  [       ] + 0.4786; R² = 0.9997 
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Table 30: Metabolites Measured 
Metabolite 
Fold change in 
cells treated 
with IL-1β+γ-IFN 
Relative to NT 
p-value 
Citrulline 431.17 2.65 x 10
-25 
Inosine 11.70 3.60 x 10
-7 
Pyruvate 7.58 2.03 x 10
-6 
TDP 2.14 8.55 x 10
-6 
Lactate -8.15 4.42 x 10
-5 
Shikimate-3-phosphate 2.20 7.20 x 10
-5 
Malate 3.78 1.38 x 10
-5 
Taurine 3.18 1.75 x 10
-4 
UDP-N-acetylglucosamine 2.98 2.12 x 10
-4 
Methylmalnic acid 2.78 3.95 x 10
-4 
4-Hydroxybenzoate 2.10 4.16 x 10
-4 
Succinate and Methylmalonate 2.75 4.48 x 10
-4 
Citrate 2.65 5.49 x 10
-4 
Citraconate 2.06 6.52 x 10
-4 
N-Acetylglucosamine-1-phosphate 1.21 1.28 x 10
-3 
D-Glyceraldehyde-3-phosphate 1.00 1.65 x 10
-3 
UDP-D-glucose 2.05 2.25 x 10
-3 
UDP 2.18 2.68 x 10
-3 
Nicotinamide ribotide -1.16 3.75 x 10
-3 
Pantothenate -1.04 4.06 x 10
-3 
dCDP 1.44 5.13 x 10
-3 
Glucose-6-phosphate 1.09 6.46 x 10
-3 
Glycerate-2,3-diphosphate -1.09 8.09 x 10
-3 
Nicotinate 1.78 8.36 x 10
-3 
Riboflavin (Vitamin B2) 1.08 0.011 
Orotidine-phosphate 1.38 0.011 
5-methyl-tetrahydrofolate -2.88 0.013 
2-Deoxyribose-1-phosphate 1.40 0.014 
1-methyladenosine -1.22 0.015 
Ceramide  -1.48 0.016 
Guanosine 2.41 0.017 
Pyridine-2,3-dicarboxylate 1.00 0.027 
Stearate 1.64 0.033 
D-Glucono-lactone-6-phosphate 1.52 0.036 
Dihydroxyacetone phosphate (DHAP) -1.09 0.038 
Pyridoxine 1.51 0.040 
Pentose-phosphate 1.85 0.044 
dATP 1.17 0.054 
Tyrosine 1.57 0.058 
ADP 1.74 0.063 
D-Hexose-phosphate -1.05 0.066 
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Table 30: Continued 
Metabolite 
Fold change in 
cells treated 
with IL-1β+γ-IFN 
Relative to NT 
p-value 
Asparagine -1.47 0.093 
NAD -1.19 0.106 
N-acetyl-glutamine 1.23 0.120 
1-methylhistidine 1.00 0.134 
5'-methylthioadenosine 1.21 0.136 
2-Keto-D-gluconate -1.50 0.139 
Glycerate-diphosphate (1,3 and 2,3) 1.19 0.140 
Aconitate (cis and trans) 1.51 0.144 
Glycerol-3-phosphate 1.70 0.148 
Methionine 1.34 0.153 
Homoserine 1.34 0.158 
Glutamate 1.35 0.162 
Carnitine -1.13 0.168 
Cytidine 2.12 0.175 
Ornithine 1.62 0.180 
Arginine -1.47 0.204 
GABA 1.29 0.228 
4-Pyridoxate 1.46 0.229 
Choline 1.10 0.238 
Acetyllysine 1.32 0.240 
5-methyldeoxycytidine 1.37 0.251 
Histidine 1.17 0.259 
Cysteine 1.25 0.264 
Proline -1.06 0.270 
5-Phosphoribosyl-1-diphosphate  1.49 0.276 
N-acetyl-glutamate  1.40 0.286 
Valine 1.48 0.295 
Acetyl phosphate 1.00 0.299 
DL-Acetylcarnitine 1.17 0.316 
Reduced glutathione  1.17 0.319 
Nicotinamide 1.31 0.352 
Lysine 1.21 0.354 
Glutamine  1.03 0.361 
Tryptophan -1.53 0.365 
Fumarate, Maleate, iso-Ketovalerate 1.31 0.369 
Phenylalanine 1.72 0.417 
S-adenosyl-L-methionine  1.13 0.436 
Threonine 1.18 0.452 
(Iso)Leucine 1.53 0.454 
Adenosine 1.32 0.460 
Palmitate -1.92 0.477 
Glycerophosphocholine 1.10 0.478 
Aspartate -1.15 0.484 
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Table 31: Metabolites Measured 
Metabolite 
Fold change in 
cells treated 
with 
Camptothecin 
Relative to NT 
p-value 
N-Acetylglucosamine-1-phosphate 3.79 1.79 x 10
-5 
Cysteine 3.59 1.83 x 10
-5 
1-methylhistidine 5.66 4.83 x 10
-5 
D-Glyceraldehyde-3-phosphate 1.50 5.23 x 10
-5 
Pantothenate 2.47 8.07 x 10
-5 
1-methyladenosine 4.83 8.41 x 10
-5 
Tryptophan 1.23 3.52 x 10
-4 
UDP-D-glucose 2.90 4.35 x 10
-4 
UDP-N-acetylglucosamine 3.10 4.99 x 10
-4 
Lactate 1.26 6.76 x 10
-4 
Methylmalnic acid 1.73 9.15 x 10
-4 
Succinate and Methylmalonate 1.72 1.09 x 10
-3 
5-methyldeoxycytidine 2.33 3.55 x 10
-3 
5-Phosphoribosyl-1-diphosphate  -1.61 4.71 x 10
-3 
Nicotinamide ribotide -2.92 5.70 x 10
-3 
Shikimate-3-phosphate 1.60 6.36 x 10
-3 
D-Hexose-phosphate 1.79 7.37 x 10
-3 
Nicotinamide -1.04 7.53 x 10
-3 
2-Keto-D-gluconate -2.09 0.010 
5'-methylthioadenosine 1.94 0.011 
Glycerol-3-phosphate 2.64 0.012 
Ornithine 2.20 0.012 
Guanosine 3.02 0.013 
Dihydroxyacetone phosphate (DHAP) 1.89 0.015 
Pentose-phosphate 2.02 0.018 
2-Deoxyribose-1-phosphate 1.43 0.019 
N-acetyl-glutamate  1.59 0.020 
Citrate 1.56 0.021 
Lysine 3.16 0.022 
Glutamine  2.65 0.023 
ADP 3.92 0.028 
Glycerate-2,3-diphosphate -1.06 0.032 
Stearate -1.26 0.033 
UDP 1.87 0.033 
GABA 2.29 0.038 
Riboflavin (Vitamin B2) 1.69 0.046 
Taurine 2.37 0.048 
Adenosine -1.44 0.049 
Inosine 1.69 0.050 
Orotidine-phosphate 1.12 0.050 
Palmitate -1.08 0.053 
Aspartate 1.64 0.062 
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Table 31: Continued 
Metabolite 
Fold change in 
cells treated 
with 
Camptothecin 
Relative to NT 
p-value 
Reduced glutathione  1.80 0.074 
Citraconate -1.01 0.075 
D-Glucono-lactone-6-phosphate 1.01 0.079 
TDP -1.24 0.084 
DL-Acetylcarnitine 2.30 0.084 
Asparagine 1.67 0.085 
Ceramide  -1.14 0.085 
Carnitine 1.48 0.089 
Glycerophosphocholine 1.70 0.089 
Proline 1.86 0.090 
dATP 1.33 0.092 
Arginine 1.67 0.101 
Nicotinate 1.66 0.104 
Tyrosine 1.74 0.105 
Glucose-6-phosphate -1.02 0.108 
Choline 1.63 0.128 
5-methyl-tetrahydrofolate -2.88 0.130 
dCDP 1.21 0.131 
Pyruvate 1.04 0.134 
Histidine 1.64 0.153 
4-Pyridoxate 1.07 0.157 
Aconitate (cis and trans) -1.29 0.193 
Citrulline 1.00 0.198 
(Iso)Leucine 1.40 0.199 
Glutamate 1.59 0.205 
Pyridine-2,3-dicarboxylate 1.00 0.206 
Acetyllysine 1.67 0.223 
Pyridoxine -1.18 0.224 
S-adenosyl-L-methionine (SAM) 2.00 0.225 
Malate 1.09 0.236 
Threonine 2.37 0.260 
Glycerate-diphosphate (1,3 and 2,3) 1.22 0.270 
N-acetyl-glutamine 1.61 0.272 
Acetyl phosphate 1.00 0.303 
Valine 1.34 0.327 
Methionine 1.59 0.339 
Homoserine 1.59 0.340 
Phenylalanine 1.41 0.343 
Cytidine 1.74 0.373 
NAD 1.07 0.381 
Fumarate, Maleate, iso-Ketovalerate -1.16 0.404 
4-Hydroxybenzoate -1.08 0.482 
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